<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        3009245990
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        XALKORI 250MG CAPSULE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CRIZOTINIB
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        250
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule, hard
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        14478.75
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="PFIZER" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            PFIZER
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 583]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ALNAGHI COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            PFIZER
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01XE16
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>XALKORI<em> </em>is an anticancer medicine containing the active substance crizotinib used to treat adults with a type of lung cancer called non-small cell lung cancer, that presents with a specific rearrangement or defect in either a gene called anaplastic lymphoma kinase (ALK) or a gene called ROS1.</p><p>&nbsp;</p><p>XALKORI<em> </em>can be prescribed to you for the initial treatment if your disease is at an advanced stage of lung cancer.</p><p>&nbsp;</p><p>XALKORI<em> </em>can be prescribed to you if your disease is at an advanced stage and previous treatment has not helped to stop your disease.</p><p>&nbsp;</p><p>XALKORI<em> </em>may slow or stop the growth of lung cancer. It may help shrink tumours.</p><p>&nbsp;</p><p>If you have any questions about how<em> </em>XALKORI<em> </em>works or why this medicine has been prescribed for you, ask your doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take XALKORI</strong></p><ul><li>If you are allergic to crizotinib or any of the other ingredients of this medicine (listed in Section&nbsp;6, &ldquo;What XALKORI contains&rdquo;).</li></ul><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor before taking XALKORI:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have moderate or severe liver disease.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have ever had any other lung problems. Some lung problems may get worse during treatment with XALKORI, as XALKORI may cause inflammation of the lungs during treatment. Symptoms may be similar to those from lung cancer. Tell your doctor right away if you have any new or worsening symptoms including difficulty in breathing, shortness of breath, or cough with or without mucous, or fever.</p><ul><li>If you have been told that you have an abnormality of your heart tracing after an electrocardiogram (ECG) known as prolonged QT&nbsp;interval.</li></ul><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have reduced heart rate.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have ever had stomach or intestine problems such as holes (perforation), or if you have conditions causing inflammation inside the abdomen (diverticulitis), or if you have spread of cancer inside the abdomen (metastasis).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have vision disorders (seeing flashes of light, blurred vision, and double vision).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have severe kidney disease.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are currently treated with any of the medicines listed in section &ldquo;Other medicines and XALKORI&rdquo;<em>.</em></p><p>&nbsp;</p><p>Talk to your doctor right away after having taken XALKORI:</p><ul><li>If you are experiencing severe stomach or abdominal pain, fever, chills, shortness of breath, fast heartbeat, partial or complete loss of vision (in one or both eyes) or changes in bowel habits.</li></ul><p>&nbsp;</p><p>Most of the available information is available in patients with some specific histology type of ALK‑positive NSCLC (adenocarcinoma) and limited information is available in the other histologies.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>Treatment of children and adolescents with this medicine is not recommended. The indication does not cover children and adolescents.</p><p>&nbsp;</p><p><strong>Other medicines and XALKORI</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including herbal medicines and medicine obtained over the counter.</p><p>&nbsp;</p><p>In particular, the following medicines may increase the risk of side effects with XALKORI:</p><ul><li>Clarithromycin, telithromycin, erythromycin, antibiotics used to treat bacterial infections.</li><li>Ketoconazole, itraconazole, posaconazole, voriconazole, used to treat fungal infections.</li></ul><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Atazanavir, ritonavir, cobicistat, used to treat HIV infections/AIDS.</p><p>&nbsp;</p><p>The following medicines may reduce the effectiveness of XALKORI:</p><p>&middot;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp; Phenytoin, carbamazepine or phenobarbital, anti‑epileptics used to treat seizures or fits.</p><ul><li>Rifabutin, rifampicin, used to treat tuberculosis.</li><li>St.&nbsp;John&rsquo;s&nbsp;wort (<em>Hypericum perforatum</em>), a herbal product used to treat depression.</li></ul><p>&nbsp;</p><p>XALKORI may increase side effects associated with the following medicines:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Alfentanil and other short acting opiates such as fentanyl (painkillers used for surgical procedures).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Quinidine, digoxin, disopyramide, amiodarone, sotalol, dofetilide, ibutilide, verapamil, diltiazem used to treat heart problems.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines for high blood pressure called beta-blockers such as atenolol, propranolol, labetolol.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pimozide, used to treat mental illness.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Metformin, used to treat diabetes.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Procainamide, used to treat cardiac arrhythmia.</p><ul><li>Cisapride, used to treat stomach problems.</li><li>Ciclosporin, sirolimus and tacrolimus used in transplant patients.</li><li>Ergot alkaloids (e.g., ergotamine, dihydroergotamine), used to treat migraine.</li><li>Dabigatran, anticoagulant used to slow down clotting of the blood.</li><li>Colchicine, used to treat gout.</li><li>Pravastatin, used to reduce cholesterol levels.</li><li>Clonidine, guanfacine, used to treat hypertension.</li><li>Mefloquine, used for the prevention of malaria.</li><li>Pilocarpine, used to treat glaucoma (a severe eye disease).</li><li>Anticholinesterases, used to restore muscle function.</li><li>Antipsychotics, used to treat mental illness.</li><li>Moxifloxacine, used to treat bacterial infections.</li><li>Methadone, used to treat pain and for the treatment of opioid dependence.</li><li>Bupropion, used to treat depression and smoking cessation.</li><li>Efavirenz, raltegravir, used to treat HIV infection.</li><li>Irinotecan, a chemotherapy medicine used to treat cancer of the colon and rectum.</li><li>Morphine, used to treat acute and cancer pain.</li><li>Naloxone, used to treat opiate medicine addiction and withdrawal.</li></ul><p>&nbsp;</p><p>These medicines<em> should be avoided </em>during your treatment with XALKORI.</p><p>&nbsp;</p><p><strong>Oral contraceptives</strong></p><p>If you take XALKORI whilst using oral contraceptives, the oral contraceptives may be ineffective.</p><p>&nbsp;</p><p><strong>XALKORI with food and drink</strong></p><p>You can take XALKORI with or without food; however, you should avoid drinking grapefruit juice or eating grapefruit while on treatment with XALKORI<em> </em>as they may change the amount of XALKORI in your body.</p><p>&nbsp;</p><p><strong>Sun protection</strong></p><p>Avoid spending prolonged time in sunlight. XALKORI can make your skin sensitive to the sun (photosensitivity), and you may burn more easily. You should wear protective clothing and/or use sunscreen that covers your skin to help protect against sunburn if you have to be in the sunlight during treatment with XALKORI.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p>Talk to your doctor or pharmacist before taking this medicine if you are pregnant, may become pregnant or are breast-feeding.</p><p>&nbsp;</p><p>It is recommended that women avoid becoming pregnant and that men do not father children during treatment with XALKORI because this medicine could harm the baby. If there is any possibility that the person taking this medicine may become pregnant or father a child, they must use adequate contraception during treatment, and for at least 90&nbsp;days after completing therapy as oral contraceptives may be ineffective while taking XALKORI.</p><p>&nbsp;</p><p>Do not breast-feed during treatment with XALKORI. XALKORI could harm a breast-fed baby.</p><p>&nbsp;</p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>You should take special care when driving and using machines as patients taking XALKORI may experience visual disturbances, dizziness, and tiredness.</p><p>&nbsp;</p><p><strong>XALKORI contains sodium</strong></p><p>This medicine contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per 200&nbsp;mg or 250&nbsp;mg capsule, that is to say essentially &lsquo;sodium‑free&rsquo;.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;</p><p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><ul><li>The recommended dose is one capsule of 250&nbsp;mg taken orally twice daily (total amount 500&nbsp;mg).</li><li>Take the capsule once in the morning and once in the evening.</li><li>Take the capsules at about the same time each day.</li><li>You can take the capsules with or without food always avoiding grapefruit.</li><li>Swallow the capsules whole and do not crush, dissolve or open the capsules.</li></ul><p>&nbsp;</p><p>If necessary, your doctor may decide to reduce the dose to 200&nbsp;mg to be taken orally twice daily (total amount 400&nbsp;mg) and if further dose reduction is necessary, to reduce it to 250&nbsp;mg to be taken orally once daily. Your doctor may decide to permanently discontinue your treatment if you are unable to tolerate XALKORI 250&nbsp;mg taken orally once daily.</p><p>&nbsp;</p><p><strong>If you take more XALKORI than you should</strong></p><p>If you accidentally take too many capsules, tell your doctor or pharmacist right away. You may require medical attention.</p><p>&nbsp;</p><p><strong>If you forget to take XALKORI</strong></p><p>What to do if you forget to take a capsule depends on how long it is until your next dose.</p><ul><li>If your next dose is in <strong>6&nbsp;hours or more</strong>, take the missed capsule as soon as you remember. Then take the next capsule at the usual time.</li><li>If your next dose is in <strong>less than 6&nbsp;hours</strong>, skip the missed capsule. Then take the next capsule at the usual time.</li></ul><p>&nbsp;</p><p>Tell your doctor about the missed dose at your next visit.</p><p>&nbsp;</p><p>Do not take a double dose (two&nbsp;capsules at the same time) to make up for a forgotten capsule.</p><p>&nbsp;</p><p>If you vomit after taking a dose of XALKORI, do not take an extra dose; just take your next dose at your regular time.</p><p>&nbsp;</p><p><strong>If you stop taking XALKORI</strong></p><p>It is important to take XALKORI every day, as long as your doctor prescribes it to you. If you are not able to take the medicine as your doctor prescribed, or you feel you do not need it anymore, contact your doctor right away.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>If you experience any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet.</p><p>&nbsp;</p><p>Some side effects could be serious. You should immediately contact your doctor if you experience any of the following serious side effects (see also section&nbsp;2 &ldquo;What you need to know before you take XALKORI &rdquo;):</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Liver failure</strong></p><p>Tell your doctor right away if you feel more tired than usual, your skin and whites of your eyes turn yellow, your urine turns dark or brown (tea colour), you have nausea, vomiting, or decreased appetite, you have pain on the right side of your stomach, you have itching, or if you bruise more easily than usual. Your doctor may do blood tests to check your liver function, and if the results are abnormal, your doctor may decide to reduce the dose of XALKORI or stop your treatment.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Lung inflammation</strong></p><p>Tell your doctor right away if you experience difficulty in breathing, especially if associated with cough or fever.</p><p>&nbsp;</p><ul><li><strong>Reduction in the number of white blood cells (including neutrophils)</strong></li></ul><p>Tell your doctor right away if you experience fever or infection. Your doctor may do blood tests and if the results are abnormal, your doctor may decide to reduce the dose of XALKORI.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Light-headedness, fainting, or chest discomfort</strong></p><p>Tell your doctor right away if you experience these symptoms which could be signs of changes in the electrical activity (seen on electrocardiogram) or abnormal rhythm of the heart. Your doctor may perform electrocardiograms to check there are no problems with your heart during treatment with XALKORI.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Partial or complete loss of vision in one or both eyes</strong></p><p>Tell your doctor right away if you experience any loss of vision or any change in vision such as difficulty seeing out of one or both eyes. Your doctor may stop XALKORI treatment and refer you to an ophthalmologist.</p><p>&nbsp;</p><p>Other side effects of XALKORI may include:</p><p>&nbsp;</p><p><em>Very common side effects</em> (may affect more than 1 in 10&nbsp;people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Visual effects (seeing flashes of light, blurred vision, or double vision, often beginning soon after starting treatment with XALKORI).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stomach upset, including vomiting, diarrhoea, nausea.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Oedema (excess fluid in body tissue, causing swelling of the hands and feet).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Constipation.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormalities in liver blood tests.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decreased appetite.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tiredness.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Neuropathy (feeling of numbness or pins and needles in the joints or extremities).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Alteration in sense of taste.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pain in the abdomen.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reduction in the number of red blood cells (anaemia).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin rash.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reduced heart rate.</p><p><em>&nbsp;</em></p><p><em>Common side effect</em>s (may affect up to 1 in 10&nbsp;people)</p><ul><li>Indigestion.</li><li>Increased blood levels of creatinine (may indicate that kidneys are not functioning properly).</li><li>Increased levels of the enzyme alkaline phosphatase in the blood (an indicator of organ malfunction or injury, particularly liver, pancreas, bone, thyroid gland, or gall bladder).</li><li>Hypophosphataemia (low blood phosphate levels that can cause confusion or muscle weakness).</li><li>Closed pouches of fluid within the kidneys (kidney cysts).</li><li>Fainting.</li><li>Inflammation of the oesophagus (swallowing tube).</li><li>Decreased levels of testosterone, a male sex hormone.</li><li>Heart failure.</li></ul><p>&nbsp;</p><p><em>Uncommon side effect</em>s (may affect up to 1 in 100&nbsp;people)</p><ul><li>Hole (perforation) in stomach or intestine.</li><li>Sensitivity to sunlight (photosensitivity).</li><li>Increased blood levels of tests that check for muscle damage (high creatine phosphokinase levels).</li></ul><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p><strong>&nbsp;</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p><p><strong>&nbsp;</strong></p><p><strong>To Report</strong><strong> side effects</strong></p><p>&nbsp;</p><ul><li>Saudi Arabia</li></ul><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:408px"><tbody><tr><td style="vertical-align:top"><p><strong>National Pharmacovigilance Center (NPC)</strong></p><p>Call center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa/&nbsp;&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p><u>&nbsp;</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC States</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:406px"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table><p><u>&nbsp;</u></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ul><li>Keep this medicine out of the sight and reach of children.</li><li>Do not use this medicine after the expiry date which is stated on the bottle or blister foil and carton after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</li><li>Store below 30&deg;C.</li><li>Do not use any pack that is damaged or shows signs of tampering.</li></ul><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance in XALKORI is crizotinib.</p><p>XALKORI 200&nbsp;mg: each capsule contains 200&nbsp;mg crizotinib</p><p>XALKORI 250&nbsp;mg: each capsule contains 250&nbsp;mg crizotinib</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are (see also section&nbsp;2 &ldquo;XALKORI contains sodium&rdquo;):</p><p><em>Capsule content</em>: colloidal anhydrous silica, microcrystalline cellulose, anhydrous calcium hydrogen phosphate, sodium starch glycolate (Type&nbsp;A), magnesium stearate.</p><p><em>Capsule shell</em>: gelatin, titanium dioxide (E171), and red iron oxide (E172).</p><p><em>Printing ink</em>: shellac, propylene glycol, potassium hydroxide, and black iron oxide (E172).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                XALKORI 200 mg is supplied as hard gelatin capsules with pink cap and white body, printed with black ink “Pfizer” on the cap, “CRZ 200” on the body.

XALKORI 250 mg is supplied as hard gelatin capsules with pink cap and body, printed with black ink “Pfizer” on the cap, “CRZ 250” on the body.

It is available in plastic bottles of 60 hard capsules.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong></p><p>&nbsp;</p><p>Pfizer Limited</p><p>Ramsgate Road</p><p>Sandwich, Kent CT13 9NJ</p><p>United Kingdom</p><p>&nbsp;</p><p><strong>Manufacturer</strong></p><p>&nbsp;</p><p>Pfizer Manufacturing Deutschland GmbH</p><p>Betriebsstatte Freiburg</p><p>Mooswaldallee 1</p><p>79090 Freiburg</p><p>Germany</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                June 2022
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>زالكوري<em> </em>هو دواء مضاد للسرطان يحتوي على المادة الفعالة كريزوتينيب، يستخدم لعلاج البالغين المصابين بنوع من سرطان الرئة يسمى سرطان الرئة غير صغير الخلايا، يظهر في صورة إعادة ترتيب بشكل محدد أو عيب في جين يدعى كيناز سرطان الغدد الليمفاوية غير متمايز الخلايا (ALK) أو في جين يسمى ROS1.</p><p>&nbsp;</p><p>يمكن أن يوصف لك زالكوري<em> </em>كعلاج أولي إذا كان سرطان الرئة الذي تعاني منه في مرحلة متقدمة.</p><p>&nbsp;</p><p>يمكن أن يوصف لك زالكوري<em> </em>إذا كان مرضك في مرحلة متقدمة ولم يساعد العلاج السابق على إيقاف تطور المرض.</p><p>&nbsp;</p><p>يمكن لزالكوري<em> </em>أن يبطئ أو يوقف نمو سرطان الرئة. ويمكن أن يساعد في تقليص الأورام.</p><p>&nbsp;</p><p>إذا كان لديك أي أسئلة حول كيفية عمل<em> </em>زالكوري<em> </em>أو سبب وصف هذا الدواء لك، فاسأل طبيبك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL"><strong>موانع استعمال زالكوري</strong></p><ul><li dir="RTL">إذا كنت مصابًا بالحساسية تجاه كريزوتينيب أو أي من المكونات الأخرى لهذا الدواء (المدرجة في القسم ٦، &quot;محتويات زالكوري&quot;).</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاحتياطات عن استعمال زالكوري</strong></p><p dir="RTL">تحدث مع طبيبك قبل تناول زالكوري:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مرض شديد أو متوسط في الكبد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد عانيت من قبل من أي مشكلات أخرى بالرئة. قد تتفاقم بعض مشكلات الرئة أثناء العلاج بزالكوري، لأن زالكوري قد يتسبب في التهاب الرئتين أثناء العلاج. قد تكون الأعراض مشابهة لأعراض سرطان الرئة. أخبر طبيبك على الفور إذا أصبت بأي أعراض جديدة أو إذا تفاقمت أعراضك بما في ذلك صعوبة التنفس وضيق التنفس، أو السعال المصحوب أو غير المصحوب بالمخاط، أو الحمى.</p><ul><li dir="RTL">إذا تم إخبارك بأنك تعاني من اختلال في ضربات قلبك، بعد عمل مخطط كهربية القلب (ECG)، يُعرف بإطالة فترة QT.</li></ul><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من انخفاض معدل نبضات القلب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد أصبت من قبل بمشكلات في المعدة أو الأمعاء مثل الثقوب (الانثقاب)، أو إذا كنت تعاني من حالات تتسبب في التهاب داخل البطن (التهاب الرتج)، أو إذا كنت تعاني من انتشار السرطان داخل البطن (السرطان النقيلي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من اضطرابات في الرؤية (رؤية ومضات من الضوء، وتغيم الرؤية، وازدواج الرؤية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مرض شديد بالكلى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تخضع حاليًا للعلاج باستخدام أي من الأدوية المدرجة في القسم &quot;الأدوية الأخرى وزالكوري&quot;.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحدث إلى طبيبك على الفور بعد تناول زالكوري:</p><ul><li dir="RTL">إذا كنت تعاني من ألم شديد في المعدة أو البطن، أو من الحمى، أو القشعريرة، أو ضيق التنفس، أو تسارع ضربات القلب، أو فقدان جزئي أو كلي للرؤية (في إحدى العينين أو كلتيهما)، أو تغيرات في عادات التبرز.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">إن معظم المعلومات المتاحة تتعلق بالمرضى الذين تظهر لديهم أنواع معينة من التركيبة النسيجية لسرطان الرئة غير صغير الخلايا (NSCLC) إيجابي كيناز سرطان الغدد الليمفاوية غير متمايز الخلايا (السرطان الغدي)، ومتاح معلومات محدودة عن أنواع التركيبات النسيجية الأخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">لا يوصى بعلاج الأطفال والمراهقين باستخدام هذا الدواء. ودواعي الاستعمال لا تشمل الأطفال والمراهقين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التداخلات الدوائية مع أخذ هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أي أدوية أخرى، بما في ذلك الأدوية العشبية والأدوية التي تحصل عليها دون وصفة طبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">على وجه الخصوص، قد تزيد الأدوية التالية من خطر حدوث آثار جانبية عند استخدامها بالتزامن مع زالكوري:</p><ul><li dir="RTL">كلاريثروميسين، تيليثروميسين، إريثروميسين، وهي مضادات حيوية تستخدم لعلاج العدوى البكتيرية.</li><li dir="RTL">كيتوكونازول، إيتراكونازول، بوساكونازول، فوريكونازول، وهي أدوية تستخدم لعلاج العدوى الفطرية.</li></ul><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>أتازانافير، ريتونافير، كوبيسيستات، وهي أدوية تستخدم لعلاج عدوى فيروس نقص المناعة البشرية (HIV)/الإيدز.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تؤدي الأدوية التالية إلى تقليل فعالية زالكوري:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp; فينيتوين، أو كاربامازيبين، أو فينوباربيتال، وهي مضادات صرع تستخدم لعلاج النوبات.</p><ul><li dir="RTL">ريفابوتين، ريفامبيسين، يستخدمان لعلاج السل.</li><li dir="RTL">نبتة سانت جون (<em>هايبريكوم</em> <em>بيرفوراتوم</em>)، وهو منتج عشبي يستخدم لعلاج الاكتئاب.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">قد يزيد زالكوري من الآثار الجانبية المرتبطة بالأدوية التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألفينتانيل والأفيونات الأخرى سريعة المفعول مثل فينتانيل (مسكنات الألم التي تستخدم في الإجراءات الجراحية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كينيدين، ديجوكسين، ديسوبيراميد، أميودارون، سوتالول، دوفيتيليد، إيبوتيليد، فيراباميل، ديلتيازيم، وهي أدوية تستخدم لعلاج مشكلات القلب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستخدمة لعلاج ضغط الدم المرتفع المسماة حاصرات مستقبلات بيتا مثل أتينولول، بروبرانولول، لابيتولول.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>بيموزيد، يستخدم لعلاج الأمراض العقلية.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>ميتفورمين، يستخدم لعلاج داء السكري.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>بروكايناميد، يستخدم لعلاج اضطراب نظم القلب.</p><ul><li dir="RTL">سيسابريد، يستخدم لعلاج مشكلات المعدة.</li><li dir="RTL">سيكلوسبورين، وسيروليموس، وتاكروليموس وهي أدوية تستخدم مع مرضى زرع الأعضاء.</li><li dir="RTL">قلويدات الإرجوت (مثل إرجوتامين، وثنائي هيدروإرجوتامين)، وهي تستخدم لعلاج الصداع النصفي.</li><li dir="RTL">دابيجاتران، مضاد للتجلط يستخدم لإبطاء معدل تخثر الدم.</li><li dir="RTL">كولشيسين، يستخدم لعلاج النقرس.</li><li dir="RTL">برافاستاتين، يستخدم لخفض مستويات الكوليسترول.</li><li dir="RTL">كلونيدين، جوانفاسين، يستخدمان لعلاج ارتفاع ضغط الدم.</li><li dir="RTL">ميفلوكين، يستخدم لمنع الإصابة بالملاريا.</li><li dir="RTL">بيلوكاربين، يستخدم لعلاج الزرق (مرض شديد يصيب العين).</li><li dir="RTL">مضادات الكولينستراز، تستخدم لاستعادة وظيفة العضلات.</li><li dir="RTL">مضادات الذهان، تستخدم لعلاج الأمراض العقلية.</li><li dir="RTL">موكسيفلوكساسين، يستخدم لعلاج العدوى البكتيرية.</li><li dir="RTL">ميثادون، يستخدم لعلاج الألم وعلاج الاعتمادية على الأفيون.</li><li dir="RTL">بوبروبيون، يستخدم لعلاج الاكتئاب وتخفيف أعراض الإقلاع عن التدخين.</li><li dir="RTL">إيفافيرينز، رالتيجرافير، يستخدمان لعلاج عدوى فيروس نقص المناعة البشرية.</li><li dir="RTL">إيرينوتيكان، دواء علاج كيميائي يستخدم لعلاج سرطان القولون والمستقيم.</li><li dir="RTL">مورفين، يستخدم لعلاج الألم الحاد وألم السرطان.</li><li dir="RTL">نالوكسون، يستخدم لعلاج إدمان الأدوية الأفيونية وانسحابها.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><em>ينبغي تجنب </em>هذه الأدوية أثناء علاجك بزالكوري.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>موانع الحمل التي تؤخذ عن طريق الفم</strong></p><p dir="RTL">إذا كنتِ تتناولين زالكوري أثناء استخدام موانع الحمل التي تؤخذ عن طريق الفم، فقد تبطل فعالية هذه الموانع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تناول زالكوري مع الطعام والشراب</strong></p><p dir="RTL">يمكنك تناول زالكوري مع أو دون تناول الطعام؛ ومع ذلك، ينبغي أن تتجنب شرب عصير الجريب فروت أو أكل فاكهة الجريب فروت أثناء العلاج باستخدام زالكوري<em> </em>لأن فعل ذلك قد يغير من كمية زالكوري بداخل جسمك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحماية من الشمس</strong></p><p dir="RTL">تجنب قضاء أوقات طويلة في ضوء الشمس. فقد يجعل زالكوري جلدك حساسًا تجاه الشمس (حساسية الضوء)، وقد تصاب بحروق بشكل أسهل. وينبغي أن ترتدي ملابس واقية و/أو تستخدم كريمًا واقيًا من الشمس لتغطية الجلد للمساعدة في الوقاية من حروق الشمس إذا كنت مضطرًا للبقاء في ضوء الشمس أثناء العلاج بزالكوري.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">تحدثي إلى طبيبكِ أو الصيدلي قبل تناول هذا الدواء إذا كنتِ حاملًا، أو إذا كان هناك أي احتمالية في أن تصبحي حاملًا أو إذا كنتِ ترضعين رضاعة طبيعية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يوصى بأن تقوم السيدات بتجنب الحمل وألا يقوم الرجال بإنجاب الأطفال أثناء العلاج باستخدام زالكوري لأن هذا الدواء قد يلحق الأذى بالطفل. إذا كان هناك أي احتمالية لأن تصبح المرأة التي تتناول هذا الدواء حاملًا أو أن ينجب الرجل الذي يتناوله طفلًا، يجب أن يستخدما وسائل منع حمل ملائمة أثناء العلاج، ولمدة ٩٠ يومًا على الأقل بعد إكمال العلاج لأن وسائل منع الحمل التي تؤخذ عن طريق الفم قد تصبح غير فعالة عند استخدامها بالتزامن مع تناول زالكوري.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا ترضعي طفلكِ رضاعة طبيعية أثناء العلاج باستخدام زالكوري. قد يلحق زالكوري الأذى بالطفل الذي يتم إرضاعه طبيعيًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنتِ حاملًا أو ترضعين رضاعة طبيعية، أو تعتقدين أنكِ ربما تكونين حاملًا أو تخططين للإنجاب، فاستشيري طبيبكِ أو الصيدلي قبل تناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تأثير زالكوري على القيادة واستخدام الآلات</strong></p><p dir="RTL">ينبغي أن تتوخى الحذر عند القيادة واستخدام الآلات لأن المرضى الذين يتناولون زالكوري قد يصابون باضطرابات في الرؤية، ودوار، وتعب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>معلومات هامة حول بعض مكونات زالكوري</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي زالكوري على الصوديوم</strong></p><p dir="RTL">يحتوي هذا الدواء على أقل من ١ مليمول من الصوديوم (٢٣ ملجم) في كل كبسولة ٢٠٠ ملجم أو ٢٥٠ ملجم، وهذا يعني أنه &quot;خال من الصوديوم&quot; بشكل أساسي.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احرص دومًا على تناول هذا الدواء تمامًا كما أخبرك طبيبك. استشر طبيبك أو الصيدلي إذا لم تكن متأكدًا مما يجب عليك فعله.</p><p dir="RTL">&nbsp;</p><ul><li dir="RTL">الجرعة الموصى بها هي كبسولة واحدة ٢٥٠ ملجم تؤخذ عن طريق الفم مرتين يوميًا (إجمالي الكمية ٥٠٠ ملجم).</li><li dir="RTL">تناول كبسولة في الصباح وأخرى في المساء.</li><li dir="RTL">تناول الكبسولات في الوقت نفسه تقريبًا من كل يوم.</li><li dir="RTL">يمكنك تناول الكبسولات مع أو دون تناول الطعام مع تجنب فاكهة الجريب فروت دائمًا.</li><li dir="RTL">ابلع الكبسولات كاملةً ولا تقم بسحقها، أو إذابتها، أو فتحها.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان ذلك ضروريًا، قد يقرر طبيبك خفض الجرعة إلى ٢٠٠ ملجم تؤخذ عن طريق الفم مرتين يوميًا (إجمالي الكمية ٤٠٠ ملجم) وإذا كان يلزم خفض الجرعة بمقدار أكبر، فسيقرر خفضها إلى ٢٥٠ ملجم تؤخذ عن طريق الفم مرة واحدة يوميًا. قد يقرر طبيبك إيقاف علاجك بشكل دائم إذا كنت غير قادر على تحمل زالكوري ٢٥٠ ملجم الذي يؤخذ عن طريق الفم مرة واحدة يوميًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجرعة الزائدة من زالكوري</strong></p><p dir="RTL">إذا تناولت عددًا مفرطًا من الكبسولات عن طريق الخطأ، فأخبر طبيبك أو الصيدلي على الفور. فقد تحتاج إلى رعاية طبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نسيان تناول جرعة زالكوري</strong></p><p dir="RTL">يعتمد ما ينبغي أن تفعله إذا نسيت تناول إحدى الكبسولات على الوقت المتبقي حتى موعد جرعتك التالية.</p><ul><li dir="RTL">إذا كانت جرعتك التالية خلال <strong>٦</strong><strong> </strong><strong>ساعات أو أكثر</strong>، فتناول الكبسولة الفائتة بمجرد أن تتذكر. ثم تناول الكبسولة التالية في الموعد المعتاد.</li><li dir="RTL">إذا كانت جرعتك التالية خلال <strong>أقل من ٦</strong><strong> </strong><strong>ساعات</strong>، فلا تتناول الكبسولة الفائتة. ثم تناول الكبسولة التالية في الموعد المعتاد.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك بشأن الجرعة الفائتة في زيارتك التالية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتناول جرعة مضاعفة (كبسولتين في الوقت نفسه) لتعويض جرعة منسية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا تقيأت بعد تناولك لجرعة من زالكوري، فلا تتناول جرعة زائدة؛ فقط تناول جرعتك التالية في موعدها المعتاد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التوقف عن تناول زالكوري</strong></p><p dir="RTL">من المهم أن تتناول زالكوري كل يوم، طوال الفترة التي يحددها لك طبيبك. إذا لم تستطع تناول هذا الدواء كما وصفه طبيبك أو إذا شعرت أنك لم تعد تحتاج إليه، فتواصل مع طبيبك على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أي أسئلة إضافية بشأن استخدام هذا الدواء، فاسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال مع جميع الأدوية، يمكن أن يسبب هذا الدواء آثارًا جانبية، إلا أنها لا تصيب الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا تعرضت لأي آثار جانبية، فتحدث إلى طبيبك أو الصيدلي أو الممرضة. يتضمن هذا أي آثار جانبية محتملة غير مدرجة في هذه النشرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تكون بعض الآثار الجانبية خطيرة. ينبغي أن تتواصل مع طبيبك على الفور إذا شعرت بأي من الآثار الجانبية الخطيرة التالية (انظر أيضًا القسم ٢ &quot;ما تحتاج إلى معرفته قبل تناول زالكوري&quot;):</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>فشل الكبد</strong></p><p dir="RTL">أخبر طبيبك على الفور إذا كنت تشعر بالتعب أكثر من المعتاد، أو إذا تحول لون جلدك وبياض عينيك إلى اللون الأصفر، أو تحول لون بولك إلى لون داكن أو بني (بلون الشاي)، أو إذا أصبت بالغثيان، أو القيء، أو انخفاض الشهية، أو إذا أصبت بألم في الجانب الأيمن من معدتك، أو إذا أصبت بالحكة، أو إذا أصبحت تصاب بكدمات بشكل أكثر سهولة من المعتاد. قد يُجري طبيبك فحوصات دم لفحص وظائف الكبد لديك، وإذا كانت النتائج غير طبيعية، فقد يقرر طبيبك أن يقلل جرعة زالكوري أو أن يوقف علاجك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>التهاب الرئة</strong></p><p dir="RTL">أخبر طبيبك على الفور إذا أصبت بصعوبة في التنفس، وخاصة إذا كانت مصحوبة بالسعال أو الحمى.</p><p dir="RTL">&nbsp;</p><ul><li dir="RTL"><strong>انخفاض في عدد خلايا الدم البيضاء </strong><strong>(</strong><strong>بما في ذلك العدلات</strong><strong>)</strong></li></ul><p dir="RTL">أخبر طبيبك على الفور إذا أصبت بحمى أو عدوى. قد يُجري طبيبك اختبارات دم، وإذا كانت النتائج غير طبيعية، فقد يقرر طبيبك أن يقلل جرعة زالكوري.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الدوخة أو الإغماء أو الانزعاج في الصدر</strong></p><p dir="RTL">أخبر طبيبك على الفور إذا أصبت بهذه الأعراض التي قد تكون علامات على التغيرات في النشاط الكهربي (يمكن رؤيته في مخطط كهربية القلب) أو اختلال نظم القلب. قد يُجري طبيبك فحوصات مخطط كهربية القلب للتأكد من عدم وجود مشكلات بقلبك أثناء العلاج بزالكوري.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الفقدان الجزئي أو الكلي للرؤية في عين واحدة أو في كلتا العينين</strong></p><p dir="RTL">أخبر طبيبك على الفور إذا أصبت بأي فقدان للرؤية أو أي تغيُّر في الرؤية مثل صعوبة الرؤية بعين واحدة أو بكلتا العينين. قد يوقف طبيبك العلاج بزالكوري ويحيلك إلى أخصائي عيون.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تتضمن الآثار الجانبية الأخرى لزالكوري:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>الآثار الجانبية الشائعة جدًا </em>(قد تصيب أكثر من شخص واحد من بين كل ١٠ أشخاص)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تأثيرات على الرؤية (رؤية ومضات من الضوء أو تغيم الرؤية أو ازدواج الرؤية، غالبًا ما تبدأ هذه التأثيرات بعد بدء العلاج بزالكوري بوقت قصير).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انزعاج بالمعدة، بما في ذلك القيء، الإسهال، الغثيان.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التورم (كمية زائدة من السوائل في أنسجة الجسم، مما يسبب تورم اليدين والقدمين).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإمساك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اختلالات في نتائج فحوصات الدم الخاصة بالكبد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض الشهية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التعب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوار.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اعتلال الأعصاب (الإحساس بالخدر أو الشكشكة والوخز في المفاصل أو الأطراف).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغير في حاسة التذوق.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في البطن.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في عدد خلايا الدم الحمراء (فقر الدم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض معدل نبضات القلب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>الآثار الجانبية الشائعة</em> (قد تصيب ما يصل إلى شخص واحد من بين كل ١٠ أشخاص)</p><ul><li dir="RTL">عسر الهضم.</li><li dir="RTL">زيادة مستويات الكرياتينين في الدم (قد يشير إلى أن الكلى لا تعمل كما ينبغي).</li><li dir="RTL">زيادة مستويات إنزيم الفوسفاتاز القلوي في الدم (وهو مؤشر لقصور وظائف أحد الأعضاء أو إصابته، وخاصة الكبد، أو البنكرياس، أو العظام، أو الغدة الدرقية أو المرارة).</li><li dir="RTL">نقص فوسفات الدم (انخفاض مستويات الفوسفات في الدم والتي يمكن أن تسبب الارتباك أو ضعف العضلات).</li><li dir="RTL">أكياس مغلقة من السوائل داخل الكليتين (تكيسات الكلى).</li><li dir="RTL">الإغماء.</li><li dir="RTL">التهاب المريء (أنبوب البلع).</li><li dir="RTL">انخفاض مستويات التيستوستيرون، أحد الهرمونات الجنسية الذكرية.</li><li dir="RTL">فشل قلب.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><em>الآثار الجانبية غير الشائعة</em> (قد تصيب ما يصل إلى شخص واحد من بين كل ١٠٠ شخص)</p><ul><li dir="RTL">ثقب (انثقاب) في المعدة أو الأمعاء.</li><li dir="RTL">الحساسية تجاه ضوء الشمس (حساسية الضوء).</li><li dir="RTL">ارتفاع مستويات المؤشرات في الدم في الاختبارات التي تفحص تلف العضلات (ارتفاع مستويات فوسفوكيناز الكرياتين في الدم).</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا أُصبت بأي أعراض جانبية، فتحدث إلى طبيبك أو الصيدلي أو الممرضة. هذا يتضمن أي أعراض جانبية محتملة غير مدرجة في هذه النشرة. بالإبلاغ عن الأعراض الجانبية فإنك تساعد في تقديم المزيد من المعلومات عن سلامة هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>للإبلاغ عن الأعراض الجانبية:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المملكة العربية السعودية</strong></p><p dir="RTL">&nbsp;</p><table dir="rtl" border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">المركز الوطني للتيقظ والسلامة الدوائية &nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مركز الاتصال: ١٩٩٩٩</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: https://ade.sfda.gov.sa</p><p dir="RTL">&nbsp;</p></td></tr></tbody></table><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>دول </strong><strong>الخليج</strong><strong> الأخرى</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong><em>- </em></strong><em>الرجاء</em><em> </em><em>الاتصال</em><em> </em><em>بالمؤسسات</em><em> </em><em>والهيئات</em><em> </em><em>الوطنية</em><em> </em><em>في</em><em> </em><em>كل</em><em> </em><em>دولة.</em></p></td></tr></tbody></table><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <ul><li>احفظ هذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</li><li>لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المُدون على الزجاجة أو رقاقة شريط البليستر المعدنية وعلى العبوة الكرتونية بعد الرمز &quot;EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى آخر يوم من الشهر المذكور.</li><li>يحفظ في درجة حرارة أقل من 30 درجة مئوية.</li><li>لا تستخدم أي عبوة تالفة أو تظهر عليها علامات عبث.</li></ul><p>&nbsp;</p><p>لا تتخلص من أي أدوية عبر مياه الصرف أو مع المخلفات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. ستساعد هذه الإجراءات على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">زالكوري ٢٠٠ ملجم: تحتوي كل كبسولة على ٢٠٠ ملجم كريزوتينيب</p><p dir="RTL">زالكوري ٢٥٠ ملجم: تحتوي كل كبسولة على ٢٥٠ ملجم كريزوتينيب</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي (انظر أيضًا القسم ٢ &quot;يحتوي زالكوري على الصوديوم&quot;):</p><p dir="RTL"><em>محتويات الكبسولة</em>: سيليكا غروية لا مائية، سيليولوز بلوري مكروي، فوسفات الكالسيوم الهيدروجيني اللامائي، جليكولات نشا الصوديوم النوع (A)، ستيارات المغنيسيوم.</p><p dir="RTL"><em>غلاف الكبسولة</em>: جيلاتين، وثاني أكسيد التيتانيوم (E171)، وأكسيد الحديد الأحمر(E172).</p><p dir="RTL"><em>حبر الطباعة</em>: صمغ اللك، وبروبيلين جليكول، وهيدروكسيد البوتاسيوم، وأكسيد الحديد الأسود (E172).</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>يرد زالكوري 200 مجم في صورة كبسولات جيلاتينية صلبة، ذات غطاء وردي وجسم أبيض، تحمل كلمة &quot;Pfizer&quot;على الغطاء و&quot;CRZ 200&quot; على الجسم مطبوعتين بالحبر الأسود. يرد زالكوري 250 مجم في صورة كبسولات جيلاتينية صلبة، ذات غطاء وردي وجسم أبيض، تحمل كلمة &quot;Pfizer&quot;على الغطاء و&quot;CRZ 250&quot; على الجسم مطبوعتين بالحبر الأسود. وهو متوفر في زجاجات بلاستيكية تحتوي على 60 كبسولة صلبة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>مالك تصريح التسويق</strong></p><p>&nbsp;</p><p>Pfizer Limited</p><p>Ramsgate Road</p><p>Sandwich, Kent CT13&nbsp;9NJ</p><p>United Kingdom، المملكة المتحدة</p><p><strong>&nbsp;</strong></p><p><strong>الجهة المصنعة</strong></p><p><strong>&nbsp;</strong></p><p>Pfizer Manufacturing Deutschland GmbH</p><p>Betriebsstatte Freiburg</p><p>Mooswaldallee 1</p><p>79090 Freiburg</p><p>Germany، ألمانيا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            يونيو 2022
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                XALKORI 200 mg hard capsules
XALKORI 250 mg hard capsules

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                XALKORI 200 mg hard capsules
Each hard capsule contains 200 mg of crizotinib.

XALKORI 250 mg hard capsules
Each hard capsule contains 250 mg of crizotinib.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hard capsule.

XALKORI 200 mg hard capsules
White opaque and pink opaque hard capsule, with “Pfizer” imprinted on the cap and “CRZ 200” on the body.

XALKORI 250 mg hard capsules
Pink opaque hard capsule, with “Pfizer” imprinted on the cap and “CRZ 250” on the body.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>XALKORI as monotherapy is indicated for:</p><p>&nbsp;</p><ul><li>The first-line treatment of adults with anaplastic lymphoma kinase (ALK)‑positive advanced non-small cell lung cancer (NSCLC)</li></ul><p>&nbsp;</p><ul><li>The treatment of adults with previously treated anaplastic lymphoma kinase (ALK)‑positive advanced non-small cell lung cancer (NSCLC)</li></ul><p>&nbsp;</p><ul><li>&nbsp;The treatment of adults with ROS1-positive advanced non-small cell lung cancer (NSCLC)</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>Treatment with XALKORI should be initiated and supervised by a physician experienced in the use of<s> </s>anticancer medicinal products.</p><p>&nbsp;</p><p><u>ALK and ROS1 testing</u></p><p><em>&nbsp;</em></p><p>An accurate and validated assay for either ALK or ROS1 is necessary for the selection of patients for treatment with<em> </em>XALKORI (see section&nbsp;5.1 for information on assays used in the clinical studies).</p><p>&nbsp;</p><p>Either ALK‑positive or ROS1‑positive NSCLC status should be established prior to initiation of crizotinib therapy. Assessment should be performed by laboratories with demonstrated proficiency in the specific technology being utilised (see section&nbsp;4.4).</p><p><em>&nbsp;</em></p><p><u>Posology</u></p><p>&nbsp;</p><p>The recommended dose schedule of XALKORI is 250&nbsp;mg twice daily (500&nbsp;mg daily) taken continuously.</p><p>&nbsp;</p><p>If a dose is missed, then it should be taken as soon as the patient remembers unless it is less than 6&nbsp;hours until the next dose, in which case the patient should not take the missed dose. Patients should not take 2&nbsp;doses at the same time to make up for a missed dose.</p><p>&nbsp;</p><p><em>Dose adjustments</em></p><p>Dosing interruption and/or dose reduction may be required based on individual safety and tolerability. In 1722&nbsp;patients treated with crizotinib with either ALK‑positive or ROS1‑positive NSCLC across clinical studies, the most frequent adverse reactions (&ge;&nbsp;3%) associated with dosing interruptions were neutropenia, elevated transaminases, vomiting, and nausea. The most frequent adverse reactions (&ge;&nbsp;3%) associated with dose reductions were elevated transaminases and neutropenia. If dose reduction is necessary for patients treated with crizotinib 250&nbsp;mg orally twice daily, then the dose of crizotinib should be reduced as below.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; First dose reduction: XALKORI 200&nbsp;mg taken orally twice daily</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Second dose reduction: XALKORI 250&nbsp;mg taken orally once daily</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Permanently discontinue if unable to tolerate XALKORI 250&nbsp;mg taken orally once daily</p><p>&nbsp;</p><p>Dose reduction guidelines for haematological and non‑haematological toxicities are provided in Tables&nbsp;1 and 2. For patients treated with a lower dose of crizotinib than 250&nbsp;mg twice daily, then follow the dose reduction guidelines provided in Tables&nbsp;1 and 2 accordingly.</p><p>&nbsp;</p><p><strong>Table&nbsp;1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>XALKORI</strong><strong> dose modification &ndash; haematological toxicities<sup>a,b</sup></strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>CTCAE<sup>c</sup> Grade</strong></p></td><td style="vertical-align:top"><p><strong>XALKORI</strong><strong> treatment</strong></p></td></tr><tr><td style="vertical-align:top"><p>Grade&nbsp;3</p></td><td style="vertical-align:top"><p>Withhold until recovery to Grade &le;&nbsp;2, then resume at the same dose schedule</p></td></tr><tr><td style="vertical-align:top"><p>Grade&nbsp;4</p></td><td style="vertical-align:top"><p>Withhold until recovery to Grade &le;&nbsp;2, then resume at the next lower dose<sup>d,e</sup></p></td></tr></tbody></table><p>a. Except lymphopenia (unless associated with clinical events, e.g., opportunistic infections).</p><p>b. For patients who develop neutropenia and leukopenia, see also sections&nbsp;4.4 and 4.8.</p><p>c. National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events</p><p>d. In case of recurrence, dosing should be withheld until recovery to Grade &le;&nbsp;2, then dosing should be resumed at 250&nbsp;mg once daily. XALKORI must be permanently discontinued in case of further Grade&nbsp;4 recurrence.</p><p>e. For patients treated with 250&nbsp;mg once daily or whose dose was reduced to 250&nbsp;mg once daily, discontinue during evaluation.</p><p>&nbsp;</p><p><strong>Table&nbsp;2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>XALKORI</strong><strong> dose modification &ndash; non-haematological toxicities</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:605px"><thead><tr><td style="vertical-align:top"><p><strong>CTCAE<sup>a </sup>Grade</strong></p></td><td style="vertical-align:top"><p><strong>XALKORI</strong><strong> treatment</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Grade&nbsp;3 or 4 alanine aminotransferase (ALT) or aspartate aminotransferase (AST) elevation with Grade&nbsp;&le;&nbsp;1 total bilirubin</p></td><td style="vertical-align:top"><p>Withhold until recovery to Grade&nbsp;&pound;&nbsp;1 or baseline, then resume at 250&nbsp;mg once daily and escalate to 200&nbsp;mg twice daily if clinically tolerated<sup>b,c</sup></p></td></tr><tr><td style="vertical-align:top"><p>Grade&nbsp;2, 3 or 4 ALT or AST elevation with concurrent Grade&nbsp;2, 3 or 4 total bilirubin elevation (in the absence of cholestasis or haemolysis)</p></td><td style="vertical-align:top"><p>Permanently discontinue</p></td></tr><tr><td style="vertical-align:top"><p>Any Grade interstitial lung disease (ILD)/pneumonitis</p></td><td style="vertical-align:top"><p>Withhold if ILD/pneumonitis is suspected, and permanently discontinue if treatment‑related ILD/pneumonitis is diagnosed<sup>d</sup></p></td></tr><tr><td style="vertical-align:top"><p>Grade&nbsp;3 QTc prolongation</p></td><td style="vertical-align:top"><p>Withhold until recovery to Grade&nbsp;&le;&nbsp;1, check and if necessary correct electrolytes, then resume at the next lower dose<sup>b,c</sup></p></td></tr><tr><td style="vertical-align:top"><p>Grade&nbsp;4 QTc prolongation</p></td><td style="vertical-align:top"><p>Permanently discontinue</p></td></tr><tr><td style="vertical-align:top"><p>Grade&nbsp;2, 3 bradycardia<sup>d,e</sup></p><p>&nbsp;</p><p>Symptomatic, may be severe and medically significant, medical intervention indicated</p></td><td style="vertical-align:top"><p>Withhold until recovery to Grade&nbsp;&le;&nbsp;1 or to heart rate&nbsp;60 or above</p><p>&nbsp;</p><p>Evaluate concomitant medicinal products known to cause bradycardia, as well as anti-hypertensive medicinal products</p><p>&nbsp;</p><p>If contributing concomitant medicinal product is identified and discontinued, or its dose is adjusted, resume at previous dose upon recovery to Grade&nbsp;&le;&nbsp;1 or to heart rate&nbsp;60 or above</p><p>&nbsp;</p><p>If no contributing concomitant medicinal product is identified, or if contributing concomitant medicinal products are not discontinued or dose modified, resume at reduced dose<sup>c</sup> upon recovery to Grade&nbsp;&le;&nbsp;1 or to heart rate&nbsp;60 or above</p></td></tr><tr><td style="vertical-align:top"><p>Grade&nbsp;4 bradycardia<sup>d,e,f</sup></p><p>&nbsp;</p><p>Life‑threatening consequences, urgent intervention indicated</p></td><td style="vertical-align:top"><p>Permanently discontinue if no contributing concomitant medicinal product is identified</p><p>&nbsp;</p><p>If contributing concomitant medicinal product is identified and discontinued, or its dose is adjusted, resume at 250&nbsp;mg once daily<sup>c</sup> upon recovery to Grade&nbsp;&le;&nbsp;1 or to heart rate&nbsp;60 or above, with frequent monitoring</p></td></tr><tr><td style="vertical-align:top"><p>Grade&nbsp;4 ocular disorder (visual loss)</p></td><td style="vertical-align:top"><p>Discontinue during evaluation of severe vision loss</p></td></tr></tbody></table><p>a. National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events</p><p>b. XALKORI must be permanently discontinued in case of further Grade&nbsp;&ge;&nbsp;3 recurrence. See sections&nbsp;4.4 and&nbsp;4.8.</p><p>c. For patients treated with 250&nbsp;mg once daily or whose dose was reduced to 250&nbsp;mg once daily, discontinue during evaluation.</p><p>d. See sections&nbsp;4.4 and 4.8.</p><p>e. Heart rate less than 60&nbsp;beats per minute (bpm).</p><p>f. Permanently discontinue for recurrence.</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>Crizotinib is extensively metabolised in the liver. Treatment with crizotinib should be used with caution in patients with hepatic impairment (see Table&nbsp;2 and sections&nbsp;4.4, 4.8 and 5.2).</p><p>&nbsp;</p><p>Based on the National Cancer Institute (NCI) classification, no starting dose adjustment of crizotinib is recommended for patients with mild hepatic impairment (either AST&nbsp;&gt;&nbsp;Upper Limit of Normal (ULN) and total bilirubin&nbsp;&le;&nbsp;ULN or any AST and total bilirubin&nbsp;&gt;&nbsp;ULN but &le;&nbsp;1.5&nbsp;&times;&nbsp;ULN). The starting crizotinib dose for patients with moderate hepatic impairment (any AST and total bilirubin&nbsp;&gt;&nbsp;1.5&nbsp;&times;&nbsp;ULN and &le;&nbsp;3&nbsp;&times;&nbsp;ULN) is recommended to be 200&nbsp;mg twice daily. The starting crizotinib dose for patients with severe hepatic impairment (any AST and total bilirubin&nbsp;&gt;&nbsp;3&nbsp;&times;&nbsp;ULN) is recommended to be 250&nbsp;mg once daily (see section&nbsp;5.2). Crizotinib dose adjustment according to Child‑Pugh classification has not been studied in patients with hepatic impairment.</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>No starting dose adjustment is recommended for patients with mild (60&nbsp;&le;&nbsp;creatinine&nbsp;clearance&nbsp;[CL<sub>cr</sub>]&nbsp;&lt;&nbsp;90&nbsp;mL/min) or moderate (30&nbsp;&le;&nbsp;CL<sub>cr</sub>&nbsp;&lt;&nbsp;60&nbsp;mL/min) renal impairment, since the population pharmacokinetic analysis indicated no clinically meaningful changes in steady‑state crizotinib exposure in these patients. Crizotinib plasma concentrations may be increased in patients with severe renal impairment (CL<sub>cr</sub>&nbsp;&lt;&nbsp;30&nbsp;mL/min). The crizotinib starting dose should be adjusted to 250&nbsp;mg taken orally once daily in patients with severe renal impairment not requiring peritoneal dialysis or haemodialysis. The dose may be increased to 200&nbsp;mg twice daily based on individual safety and tolerability after at least 4&nbsp;weeks of treatment (see sections&nbsp;4.4 and 5.2).</p><p>&nbsp;</p><p><em>Elderly</em></p><p>No starting dose adjustment is required (see sections&nbsp;5.1 and 5.2).</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The safety and efficacy of crizotinib in paediatric patients has not been established. No data are available.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>&nbsp;</p><p>The capsules should be swallowed whole preferably with water, and should not be crushed, dissolved, or opened. They may be taken with or without food. Grapefruit or grapefruit juice should be avoided since it may increase crizotinib plasma concentration; St.&nbsp;John&rsquo;s&nbsp;wort should be avoided since it may decrease crizotinib plasma concentration (see section&nbsp;4.5).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to crizotinib or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Assessment of ALK and ROS1 status</u></p><p><u>&nbsp;</u></p><p>When assessing either ALK or ROS1 status of a patient, it is important that a well‑validated and robust methodology is chosen to avoid false negative or false positive determinations.</p><p><u>&nbsp;</u></p><p><u>Hepatotoxicity</u></p><p>&nbsp;</p><p>Drug‑induced hepatotoxicity (including cases with fatal outcome) has been reported in patients treated with crizotinib across clinical studies (see section&nbsp;4.8). Liver function tests including ALT, AST, and total bilirubin should be monitored once a week during the first 2&nbsp;months of treatment, then once a month and as clinically indicated, with more frequent repeat testing for Grades&nbsp;2, 3 or 4 elevations. For patients who develop transaminase elevations, see section&nbsp;4.2.</p><p><u>&nbsp;</u></p><p><u>Interstitial lung disease/pneumonitis</u></p><p>&nbsp;</p><p>Severe, life‑threatening, or fatal interstitial lung disease (ILD)/pneumonitis can occur in patients treated with crizotinib. Patients with pulmonary symptoms indicative of ILD/pneumonitis should be monitored. Crizotinib treatment should be withheld if ILD/pneumonitis is suspected. Drug‑induced ILD/pneumonitis should be considered in the differential diagnosis of patients with ILD‑like conditions such as: pneumonitis, radiation pneumonitis, hypersensitivity pneumonitis, interstitial pneumonitis, pulmonary fibrosis, acute respiratory distress syndrome (ARDS), alveolitis, lung infiltration, pneumonia, pulmonary oedema, chronic obstructive pulmonary disease, pleural effusion, aspiration pneumonia, bronchitis, obliterative bronchiolitis, and bronchiectasis. Other potential causes of ILD/pneumonitis should be excluded, and crizotinib should be permanently discontinued in patients diagnosed with treatment‑related ILD/pneumonitis (see sections&nbsp;4.2 and 4.8).</p><p><u>&nbsp;</u></p><p><u>QT interval prolongation</u></p><p>&nbsp;</p><p>QTc&nbsp;prolongation has been observed in clinical studies in patients treated with crizotinib (see sections&nbsp;4.8 and 5.2) which may lead to an increased risk for ventricular tachyarrhythmias (e.g.,&nbsp;<em>Torsade de Pointes</em>) or sudden death. The benefits and potential risks of crizotinib should be considered before beginning therapy in patients with pre‑existing bradycardia, who have a history of or predisposition for QTc&nbsp;prolongation, who are taking antiarrhythmics or other medicinal products that are known to prolong QT&nbsp;interval and in patients with relevant pre‑existing cardiac disease and/or electrolyte disturbances. Crizotinib should be administered with caution in these patients and periodic monitoring of electrocardiograms (ECG), electrolytes and renal function is required. When using crizotinib, ECG and electrolytes (e.g., calcium, magnesium, potassium) should be obtained as close as possible prior to the first dose and periodic monitoring with ECGs and electrolytes is recommended, especially at the beginning of treatment in case of vomiting, diarrhoea, dehydration or impaired renal function. Correct electrolytes as necessary. If QTc increases by greater than or equal to 60 msec from baseline but QTc is &lt;&nbsp;500&nbsp;msec, crizotinib should be withheld and cardiologist advice should be sought. If QTc increases to greater than or equal to 500&nbsp;msec, cardiologist advice must be immediately sought. For patients who develop QTc prolongation, see sections&nbsp;4.2, 4.8 and 5.2.</p><p><u>&nbsp;</u></p><p><u>Bradycardia</u></p><p><u>&nbsp;</u></p><p>All-causality bradycardia was reported in clinical studies in 13% of patients treated with crizotinib. Symptomatic bradycardia (e.g., syncope, dizziness, hypotension) can occur in patients receiving crizotinib. The full effect of crizotinib on reduction of heart rate may not develop until several weeks after start of treatment. Avoid using crizotinib in combination with other bradycardic agents (e.g.,&nbsp;beta‑blockers, non‑dihydropyridine calcium channel blockers such as verapamil and diltiazem, clonidine, digoxin) to the extent possible, due to the increased risk of symptomatic bradycardia. Monitor heart rate and blood pressure regularly. Dose modification is not required in cases of asymptomatic bradycardia. For management of patients who develop symptomatic bradycardia, see Dose Modification and Undesirable Effects sections (see sections&nbsp;4.2 and 4.8).</p><p>&nbsp;</p><p><u>Cardiac failure</u></p><p>&nbsp;</p><p>In clinical studies with crizotinib and during post‑marketing surveillance, severe, life-threatening, or fatal adverse reactions of cardiac failure were reported (see section&nbsp;4.8).</p><p>&nbsp;</p><p>Patients with or without pre‑existing cardiac disorders, receiving crizotinib, should be monitored for signs and symptoms of heart failure (dyspnoea, oedema, rapid weight gain from fluid retention). Dosing interruption, dose reduction, or discontinuation should be considered as appropriate if such symptoms are observed.</p><p><u>&nbsp;</u></p><p><u>Neutropenia and leukopenia</u></p><p><u>&nbsp;</u></p><p>In clinical studies with crizotinib in patients with either ALK‑positive or ROS1‑positive NSCLC, Grade&nbsp;3 or 4 neutropenia has been very commonly (12%) reported. Grade&nbsp;3 or 4 leukopenia has been commonly (3%) reported (see section&nbsp;4.8). Less than 0.5% of patients experienced febrile neutropenia in clinical studies with crizotinib. Complete blood counts including differential white blood cell counts should be monitored as clinically indicated, with more frequent repeat testing if Grade&nbsp;3 or 4 abnormalities are observed, or if fever or infection occurs (see section&nbsp;4.2).</p><p>&nbsp;</p><p><u>Gastrointestinal perforation</u></p><p>&nbsp;</p><p>In clinical studies with crizotinib, events of gastrointestinal perforations were reported. There were reports of fatal cases of gastrointestinal perforation during post-marketing use of crizotinib (see&nbsp;section&nbsp;4.8).</p><p>&nbsp;</p><p>Crizotinib should be used with caution in patients at risk for gastrointestinal perforation (e.g., history of diverticulitis, metastases to the gastrointestinal tract, concomitant use of medicinal products with a recognised risk of gastrointestinal perforation).</p><p>&nbsp;</p><p>Crizotinib should be discontinued in patients who develop gastrointestinal perforation. Patients should be informed of the first signs of gastrointestinal perforations and be advised to consult rapidly in case of occurrence.</p><p><u>&nbsp;</u></p><p><u>Renal effects</u></p><p><u>&nbsp;</u></p><p>Blood creatinine increase and creatinine clearance decreased were observed in patients in clinical studies with crizotinib. Renal failure and acute renal failure were reported in patients treated with crizotinib in clinical studies and during post‑marketing. Cases with fatal outcome, cases requiring haemodialysis and cases of Grade&nbsp;4 hyperkalaemia were also observed. Monitoring of patients for renal function at baseline and during therapy with crizotinib is recommended, with particular attention to those who have risk factors or previous history of renal impairment (see section&nbsp;4.8).</p><p><u>&nbsp;</u></p><p><u>Renal impairment</u></p><p><u>&nbsp;</u></p><p>If patients have severe renal impairment not requiring peritoneal dialysis or haemodialysis, the dose of crizotinib should be adjusted (see sections&nbsp;4.2 and 5.2).</p><p><u>&nbsp;</u></p><p><u>Visual effects</u></p><p><u>&nbsp;</u></p><p>In clinical studies with crizotinib in patients with either ALK‑positive or ROS1‑positive NSCLC (N=1722), Grade 4 visual field defect with vision loss has been reported in 4&nbsp;(0.2%)&nbsp;patients. Optic atrophy and optic nerve disorder have been reported as potential causes of vision loss.</p><p>&nbsp;</p><p>In patients with new onset of severe visual loss (best corrected visual acuity less than 6/60&nbsp;in one&nbsp;or both eyes), crizotinib treatment should be discontinued (see section&nbsp;4.2). Ophthalmological evaluation consisting of best corrected visual acuity, retinal photographs, visual fields, optical coherence tomography (OCT) and other evaluations as appropriate for new onset of severe visual loss, should be performed. There is insufficient information to characterise the risks of resumption of crizotinib in patients with a severe visual loss. A decision to resume crizotinib should consider the potential benefit to the patient.</p><p>&nbsp;</p><p>Ophthalmological evaluation is recommended if vision disorder persists or worsens in severity (see&nbsp;section&nbsp;4.8).</p><p><u>&nbsp;</u></p><p><u>Photosensitivity</u></p><p>Photosensitivity has been reported in patients treated with Xalkori (see section&nbsp;4.8). Patients should be advised to avoid prolonged sun exposure while taking Xalkori and, when outdoors, to take protective measures (e.g., use of protective clothing and/or sunscreen).</p><p><u>&nbsp;</u></p><p><u>Drug‑drug interactions</u></p><p>&nbsp;</p><p>The concomitant use of crizotinib with strong CYP3A4&nbsp;inhibitors or with strong and moderate CYP3A4&nbsp;inducers should be avoided (see section&nbsp;4.5).</p><p>&nbsp;</p><p>The concomitant use of crizotinib with CYP3A4&nbsp;substrates with narrow therapeutic indices should be avoided (see section&nbsp;4.5). Avoid using crizotinib in combination with other bradycardic agents, medicinal products that are known to prolong QT&nbsp;interval and/or antiarrhythmics (see section&nbsp;4.4 QT&nbsp;interval prolongation, Bradycardia, and section&nbsp;4.5).</p><p>&nbsp;</p><p><u>Drug‑food interaction</u></p><p><u>&nbsp;</u></p><p>Grapefruit or grapefruit juice should be avoided during treatment with crizotinib (see sections&nbsp;4.2 and&nbsp;4.5).</p><p>&nbsp;</p><p><u>Non‑adenocarcinoma histology</u></p><p><u>&nbsp;</u></p><p>Limited information is available in patients with ALK‑positive and ROS1‑positive NSCLC with non‑adenocarcinoma histology, including squamous cell carcinoma (SCC) (see section&nbsp;5.1).</p><p>&nbsp;</p><p><u>Dietary sodium</u></p><p>&nbsp;</p><p>This medicinal product contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per 200&nbsp;mg or 250&nbsp;mg capsule, that is to say essentially &lsquo;sodium‑free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p><u>Pharmacokinetic interactions</u></p><p><em><u>&nbsp;</u></em></p><p><em>Agents that may increase crizotinib plasma concentrations</em></p><p>Coadministration of crizotinib with strong CYP3A&nbsp;inhibitors is expected to increase crizotinib plasma concentrations. Coadministration of a single 150&nbsp;mg oral dose of crizotinib in the presence of ketoconazole (200&nbsp;mg twice daily), a strong CYP3A&nbsp;inhibitor, resulted in increases in crizotinib systemic exposure, with crizotinib area‑under‑the‑plasma‑concentration versus time curve from time zero to infinity (AUC<sub>inf</sub>) and maximum observed plasma concentration (C<sub>max</sub>) values that were approximately 3.2‑fold and 1.4‑fold, respectively, those seen when crizotinib was administered alone.</p><p>&nbsp;</p><p>Coadministration of repeated doses of crizotinib (250&nbsp;mg once daily) with repeated doses of itraconazole (200&nbsp;mg once daily), a strong CYP3A&nbsp;inhibitor, resulted in increases in crizotinib steady‑state AUC<sub>tau</sub> and C<sub>max</sub>, that were approximately 1.6‑fold and 1.3‑fold, respectively, those seen when crizotinib was administered alone.</p><p>&nbsp;</p><p>Therefore, the concomitant use of strong CYP3A&nbsp;inhibitors (including but not limited to atazanavir, ritonavir, cobicistat, itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, telithromycin, and erythromycin) should be avoided. Unless the potential benefit to the patient outweighs the risk, in which case patients should be closely monitored for crizotinib adverse events (see section&nbsp;4.4).</p><p>&nbsp;</p><p>Physiologically‑based pharmacokinetic (PBPK) simulations predicted a 17% increase in crizotinib steady‑state AUC after treatment with the moderate CYP3A&nbsp;inhibitors, diltiazem or verapamil. Caution is therefore recommended in case of coadministration of crizotinib with moderate CYP3A&nbsp;inhibitors.</p><p>&nbsp;</p><p>Grapefruit or grapefruit juice may also increase plasma concentrations of crizotinib and should be avoided (see sections&nbsp;4.2 and 4.4).</p><p>&nbsp;</p><p><em>Agents that may decrease crizotinib plasma concentrations</em></p><p>Coadministration of repeated doses of crizotinib (250&nbsp;mg twice daily) with repeated doses of rifampicin (600&nbsp;mg once daily), a strong CYP3A4&nbsp;inducer, resulted in 84% and 79% decreases in crizotinib steady‑state AUC<sub>tau</sub> and C<sub>max</sub>, respectively, compared to when crizotinib was given alone. The concurrent use of strong CYP3A&nbsp;inducers, including but not limited to carbamazepine, phenobarbital, phenytoin, rifampicin, and St.&nbsp;John&rsquo;s&nbsp;wort, should be avoided (see section&nbsp;4.4).</p><p>&nbsp;</p><p>The effect of a moderate inducer including but not limited to efavirenz or rifabutin is not clearly established; therefore, their combination with crizotinib should be also avoided (see section&nbsp;4.4).</p><p>&nbsp;</p><p><em>Coadministration with medicinal products that increase gastric&nbsp;pH</em></p><p>The aqueous solubility of crizotinib is pH dependent, with low&nbsp;(acidic)&nbsp;pH resulting in higher solubility. Administration of a single 250&nbsp;mg crizotinib dose following treatment with esomeprazole 40&nbsp;mg once daily for 5&nbsp;days resulted in an approximately 10% decrease in crizotinib total exposure (AUC<sub>inf</sub>) and no change in peak exposure (C<sub>max</sub>); the extent of the change in total exposure was not clinically meaningful. Therefore, starting dose adjustment is not required when crizotinib is coadministered with agents that increase gastric&nbsp;pH (such as proton-pump inhibitors, H2 blockers, or antacids).</p><p>&nbsp;</p><p><em>Agents whose plasma concentrations may be altered by crizotinib</em></p><p>Following 28&nbsp;days of crizotinib dosing at 250&nbsp;mg taken twice daily in cancer patients, the oral midazolam AUC<sub>inf</sub> was 3.7‑fold of those seen when midazolam was administered alone, suggesting that crizotinib is a moderate inhibitor of CYP3A. Therefore, coadministration of crizotinib with CYP3A&nbsp;substrates with narrow therapeutic indices, including but not limited to alfentanil, cisapride, cyclosporine, ergot derivatives, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus should be avoided (see section&nbsp;4.4). If the combination is needed, then close clinical monitoring should be exercised.</p><p>&nbsp;</p><p><em>In vitro</em> studies indicated that crizotinib is an inhibitor of CYP2B6. Therefore, crizotinib may have the potential to increase plasma concentrations of coadministered medicinal products that are metabolised by CYP2B6 (e.g., bupropion, efavirenz).</p><p>&nbsp;</p><p><em>In vitro</em> studies in human hepatocytes indicated that crizotinib may induce pregnane&nbsp;X&nbsp;receptor (PXR)‑ and constitutive androstane receptor (CAR)‑regulated enzymes (e.g., CYP3A4, CYP2B6, CYP2C8, CYP2C9, UGT1A1). However, there was no observed induction <em>in vivo</em> when crizotinib was coadministered with the CYP3A probe substrate midazolam. Caution should be exercised in administering crizotinib in combination with medicinal products that are predominantly metabolised by these enzymes. Of note, the effectiveness of concomitant administration of oral contraceptives may be reduced.</p><p>&nbsp;</p><p><em>In vitro</em> studies indicated that crizotinib is a weak inhibitor of uridine diphosphate glucuronosyltransferase (UGT)1A1 and UGT2B7. Therefore, crizotinib may have the potential to increase plasma concentrations of coadministered medicinal products that are metabolised predominantly by UGT1A1 (e.g., raltegravir, irinotecan) or UGT2B7 (e.g., morphine, naloxone).</p><p>&nbsp;</p><p>Based on an <em>in vitro</em> study, crizotinib is predicted to inhibit intestinal P‑gp. Therefore, administration of crizotinib with medicinal products that are substrates of P‑gp (e.g., digoxin, dabigatran, colchicine, pravastatin) may increase their therapeutic effect and adverse reactions. Close clinical surveillance is recommended when crizotinib is administered with these medicinal products.</p><p>&nbsp;</p><p>Crizotinib is an inhibitor of OCT1 and OCT2 <em>in vitro</em>. Therefore, crizotinib may have the potential to increase plasma concentrations of coadministered medicinal products that are substrates of OCT1 or OCT2 (e.g.,&nbsp;metformin, procainamide).</p><p>&nbsp;</p><p><u>Pharmacodynamic interactions</u></p><p>&nbsp;</p><p>In clinical studies, prolonged QT&nbsp;interval was observed with crizotinib. Therefore, the concomitant use of crizotinib with medicinal products known to prolong QT&nbsp;interval or medicinal products able to induce <em>Torsades de pointes </em>(e.g., class&nbsp;IA [quinidine, disopyramide] or class&nbsp;III [e.g., amiodarone, sotalol, dofetilide, ibutilide], methadone, cisapride, moxifloxacine, antipsychotics, etc.) should be carefully considered. A monitoring of the QT&nbsp;interval should be made in case of combinations of such medicinal products (see sections&nbsp;4.2 and 4.4).</p><p>&nbsp;</p><p>Bradycardia has been reported during clinical studies; therefore, use crizotinib with caution due to the risk of excessive bradycardia when used in combination with other bradycardic agents (e.g.,&nbsp;non‑dihydropyridine calcium channel blockers such as verapamil and diltiazem, beta‑blockers, clonidine, guanfacine, digoxin, mefloquine, anticholinesterases, pilocarpine) (see sections&nbsp;4.2 and 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential </u></p><p><u>&nbsp;</u></p><p>Women of childbearing potential should be advised to avoid becoming pregnant while receiving XALKORI.</p><p><strong>&nbsp;</strong></p><p><u>Contraception in males and females</u></p><p>&nbsp;</p><p>Adequate contraceptive methods should be used during therapy, and for at least 90&nbsp;days after completing therapy (see section&nbsp;4.5).</p><p><u>&nbsp;</u></p><p><u>Pregnancy</u></p><p>&nbsp;</p><p>XALKORI may cause foetal harm when administered to a pregnant woman. Studies in animals have shown reproductive toxicity (see section&nbsp;5.3).</p><p>&nbsp;</p><p>There are no data in pregnant women using crizotinib. This medicinal product should not be used during pregnancy unless the clinical condition of the mother requires treatment. Pregnant women, or patients becoming pregnant while receiving crizotinib, or treated male patients as partners of pregnant women, should be apprised of the potential hazard to the foetus.</p><p>&nbsp;</p><p><u>Breast‑feeding</u></p><p><em>&nbsp;</em></p><p>It is not known whether crizotinib and its metabolites are excreted in human milk. Because of the potential harm to the infant, mothers should be advised to avoid breast-feeding while receiving XALKORI (see section&nbsp;5.3).</p><p>&nbsp;</p><p><u>Fertility</u></p><p><strong>&nbsp;</strong></p><p>Based on non-clinical safety findings, male and female fertility may be compromised by treatment with XALKORI (see section&nbsp;5.3). Both men and women should seek advice on fertility preservation before treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>XALKORI has minor influence on the ability to drive and use machines. Caution should be exercised when driving or operating machines as patients may experience symptomatic bradycardia (e.g., syncope, dizziness, hypotension), vision disorder, or fatigue while taking<em> </em>XALKORI (see sections&nbsp;4.2, 4.4 and 4.8)<em>.</em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong></p><p><u>Summary of the safety profile</u></p><p><u>&nbsp;</u></p><p>The data described below reflect exposure to XALKORI in 1669&nbsp;patients with ALK‑positive advanced NSCLC who participated in 2&nbsp;randomised Phase&nbsp;3 studies (Studies&nbsp;1007 and 1014) and in 2&nbsp;single‑arm studies (Studies&nbsp;1001 and 1005), and in 53&nbsp;patients with ROS1‑positive advanced NSCLC who participated in single‑arm Study&nbsp;1001, for a total of 1722&nbsp;patients (see section&nbsp;5.1). These patients received a starting oral dose of 250&nbsp;mg taken twice daily continuously. In Study&nbsp;1014, the median duration of study treatment was 47&nbsp;weeks for patients in the crizotinib arm (N=171); the median duration of treatment was 23&nbsp;weeks for patients who crossed over from the chemotherapy arm to receive crizotinib treatment (N=109). In Study&nbsp;1007, the median duration of study treatment was 48&nbsp;weeks for patients in the crizotinib arm (N=172). For ALK‑positive NSCLC patients in Studies&nbsp;1001 (N=154) and 1005 (N=1063), the median duration of treatment was 57 and 45&nbsp;weeks, respectively. For ROS1‑positive NSCLC patients in Study&nbsp;1001 (N=53), the median duration of treatment was 101&nbsp;weeks.</p><p>&nbsp;</p><p>The most serious adverse reactions in 1722&nbsp;patients with either ALK‑positive or ROS1‑positive advanced NSCLC were hepatotoxicity, ILD/pneumonitis, neutropenia, and QT&nbsp;interval prolongation (see section 4.4). The most common adverse reactions (&ge;&nbsp;25%) in patients with either ALK‑positive or ROS1‑positive NSCLC were vision disorder, nausea, diarrhoea, vomiting, oedema, constipation, elevated transaminases, fatigue, decreased appetite, dizziness, and neuropathy.</p><p>&nbsp;</p><p>The most frequent adverse reactions (&ge;&nbsp;3%, all‑causality frequency) associated with dosing interruptions were neutropaenia&nbsp;(11%), elevated transaminases&nbsp;(7%), vomiting&nbsp;(5%), and nausea&nbsp;(4%). The most frequent adverse reactions (&ge;&nbsp;3%, all‑causality frequency) associated with dose reductions were elevated transaminases&nbsp;(4%) and neutropaenia&nbsp;(3%). All‑causality adverse events associated with permanent treatment discontinuation occurred in 302&nbsp;(18%)&nbsp;patients of which the most frequent (&ge;&nbsp;1%) were ILD&nbsp;(1%) and elevated transaminases&nbsp;(1%).</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>&nbsp;</p><p>Table&nbsp;3 presents adverse reactions reported in 1722&nbsp;patients with either ALK‑positive or ROS1‑positive advanced NSCLC who received crizotinib across 2&nbsp;randomised Phase&nbsp;3 studies (1007&nbsp;and 1014) and 2&nbsp;single‑arm clinical studies (1001 and 1005) (see section&nbsp;5.1).</p><p>&nbsp;</p><p>The adverse reactions listed in Table&nbsp;3 are presented by system organ class and frequency categories, defined using the following convention: very common&nbsp;(&ge;&nbsp;1/10); common&nbsp;(&ge;&nbsp;1/100&nbsp;to&nbsp;&lt;&nbsp;1/10), uncommon&nbsp;(&ge;&nbsp;1/1,000&nbsp;to&nbsp;&lt;&nbsp;1/100), rare&nbsp;(&ge;&nbsp;1/10,000&nbsp;to&nbsp;&lt;&nbsp;1/1,000), very rare&nbsp;(&lt;&nbsp;1/10,000), not known (cannot be estimated from the available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><p>&nbsp;</p><p><strong>Table 3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adverse reactions reported in crizotinib clinical studies (N=1722)</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:top"><p><strong>System organ class</strong><strong> </strong></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td><td style="vertical-align:top"><p>Neutropaenia<sup>a</sup> (22%)</p><p>Anaemia<sup>b</sup> (15%)</p><p>Leukopenia<sup>c</sup> (15%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td><td style="vertical-align:top"><p>Decreased appetite (30%)</p></td><td style="vertical-align:top"><p>Hypophosphataemia (6%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p>Neuropathy<sup>d</sup> (25%)</p><p>Dysgeusia (21%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Eye disorders</strong></p></td><td style="vertical-align:top"><p>Vision disorder<sup>e</sup> (63%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td><td style="vertical-align:top"><p>Dizziness<sup>f</sup> (26%)</p><p>Bradycardia<sup>g </sup>(13%)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Cardiac failure<sup>h</sup> (1%)</p><p>Electrocardiogram QT prolonged (4%)</p><p>Syncope (3%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Interstitial lung disease<sup>i</sup> (3%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top"><p>Vomiting (51%)</p><p>Diarrhoea (54%)</p><p>Nausea (57%)</p><p>Constipation (43%)</p><p>Abdominal pain<sup>j</sup> (21%)</p></td><td style="vertical-align:top"><p>Oesophagitis<sup>k</sup> (2%)</p><p>Dyspepsia (8%)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Gastrointestinal perforation<sup>l</sup> (&lt;&nbsp;1%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td><td style="vertical-align:top"><p>Elevated transaminases<sup>m</sup> (32%)</p></td><td style="vertical-align:top"><p>Blood alkaline phosphatase increased (7%)</p></td><td style="vertical-align:top"><p>Hepatic failure (&lt;&nbsp;1%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top"><p>Rash (13%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Photosensitivity (&lt;&nbsp;1%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Renal cyst<sup>n</sup> (3%)</p><p>Blood creatinine increased<sup>o</sup> (8%)</p></td><td style="vertical-align:top"><p>Acute renal failure (&lt;&nbsp;1%)</p><p>Renal failure (&lt;&nbsp;1%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td><td style="vertical-align:top"><p>Oedema<sup>p</sup> (47%)</p><p>Fatigue (30%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Investigations</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Blood testosterone decreased<sup>q </sup>(2%)</p></td><td style="vertical-align:top"><p>Blood creatine phosphokinase increased (&lt;&nbsp;1%)<sup>*</sup></p></td></tr></tbody></table><p>Event terms that represent the same medical concept or condition were grouped together and reported as a single adverse drug reaction in Table&nbsp;3. Terms actually reported in the study up to the data cutoff date and contributing to the relevant adverse drug reaction are indicated in parentheses, as listed below.</p><p>*<sup> </sup>Creatine phosphokinase was not a standard laboratory test in the crizotinib clinical trials.</p><p>a. Neutropaenia (Febrile neutropaenia, Neutropaenia, Neutrophil count decreased).</p><p>b. Anaemia (Anaemia, Haemoglobin decreased, Hypochromic anaemia).</p><p>c. Leukopenia (Leukopenia, White blood cell count decreased).</p><p>d. Neuropathy (Burning sensation, Dysaesthesia, Formication, Gait disturbance, Hyperaesthesia, Hypoaesthesia, Hypotonia, Motor dysfunction, Muscle atrophy, Muscular weakness, Neuralgia, Neuritis, Neuropathy peripheral, Neurotoxicity, Paraesthesia, Peripheral motor neuropathy, Peripheral sensorimotor neuropathy, Peripheral sensory neuropathy, Peroneal nerve palsy, Polyneuropathy, Sensory disturbance, Skin burning sensation).</p><p>e. Vision disorder (Diplopia, Halo vision, Photophobia, Photopsia, Vision blurred, Visual acuity reduced, Visual brightness, Visual impairment, Visual perseveration, Vitreous floaters).</p><p>f. Dizziness (Balance disorder, Dizziness, Dizziness postural, Presyncope).</p><p>g. Bradycardia (Bradycardia, Heart rate decreased, Sinus bradycardia).</p><p>h. Cardiac failure (Cardiac failure, Cardiac failure congestive, Ejection fraction decreased, Left ventricular failure, Pulmonary oedema). Across clinical studies (n=1722), 19&nbsp;(1.1%)&nbsp;patients treated with crizotinib had any grade cardiac failure, 8&nbsp;(0.5%)&nbsp;patients had Grade&nbsp;3 or 4, and 3&nbsp;(0.2%)&nbsp;patients had fatal outcome.</p><p>i. Interstitial lung disease (Acute respiratory distress syndrome, Alveolitis, Interstitial lung disease, Pneumonitis).</p><p>j. Abdominal pain (Abdominal discomfort, Abdominal pain, Abdominal pain lower, Abdominal pain upper, Abdominal tenderness).</p><p>k. Oesophagitis (Oesophagitis, Oesophageal ulcer).</p><p>l. Gastrointestinal perforation (Gastrointestinal perforation, Intestinal perforation, Large intestine perforation).</p><p>m. Elevated transaminases (Alanine aminotransferase increased, Aspartate aminotransferase increased, Gamma‑glutamyltransferase increased, Hepatic enzyme increased, Hepatic function abnormal, Liver function test abnormal, Transaminases increased).</p><p>n. Renal cyst (Renal abscess, Renal cyst, Renal cyst haemorrhage, Renal cyst infection).</p><p>o. Blood creatinine increased (blood creatinine increased, creatinine renal clearance decreased).</p><p>p. Oedema (Face oedema, Generalised oedema, Local swelling, Localised oedema, Oedema, Oedema peripheral, Periorbital oedema).</p><p>q. Blood testosterone decreased (Blood testosterone decreased, Hypogonadism, Secondary hypogonadism).</p><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p><u>&nbsp;</u></p><p><em>Hepatotoxicity</em></p><p>Medicinal product‑induced hepatotoxicity with fatal outcome occurred in 0.1% of 1722&nbsp;patients treated with crizotinib across clinical studies. Concurrent elevations in ALT and/or AST&nbsp;&ge;&nbsp;3&nbsp;&times;&nbsp;ULN and total bilirubin&nbsp;&ge;&nbsp;2&nbsp;&times;&nbsp;ULN without significant elevations of alkaline phosphatase (&le;&nbsp;2&nbsp;&times;&nbsp;ULN) have been observed in less than 1%&nbsp;patients treated with crizotinib.</p><p>&nbsp;</p><p>Increases to Grade&nbsp;3 or 4 ALT or AST elevations were observed in 187&nbsp;(11%) and 95&nbsp;(6%) of patients, respectively. Seventeen&nbsp;(1%)&nbsp;patients required permanent discontinuation from treatment associated with elevated transaminases, suggesting that these events were generally manageable by dosing modifications as defined in Table&nbsp;2 (see section&nbsp;4.2). In randomised Phase&nbsp;3&nbsp;Study&nbsp;1014, increases to Grade&nbsp;3 or 4 ALT or AST elevations were observed in 15% and 8% of patients receiving crizotinib versus 2% and 1% of patients receiving chemotherapy. In randomised Phase&nbsp;3 Study&nbsp;1007, increases to Grade&nbsp;3 or 4 ALT or AST elevations were observed in 18% and 9% of patients receiving crizotinib and 5% and &lt;&nbsp;1% of patients receiving chemotherapy.</p><p>&nbsp;</p><p>Transaminase elevations generally occurred within the first 2&nbsp;months of treatment. Across studies with crizotinib in patients with either ALK‑positive or ROS1‑positive NSCLC, median time to onset of increased Grade&nbsp;1 or 2 transaminases was 23&nbsp;days. Median time to onset of increased Grade&nbsp;3 or 4 transaminases was 43&nbsp;days.</p><p>&nbsp;</p><p>Grade&nbsp;3 and 4 transaminase elevations were generally reversible upon dosing interruption. Across studies with crizotinib in patients with either ALK‑positive or ROS1‑positive NSCLC (N=1722), dose reductions associated with transaminase elevations occurred in 76&nbsp;(4%)&nbsp;patients. Seventeen&nbsp;(1%)&nbsp;patients required permanent discontinuation from treatment.</p><p>&nbsp;</p><p>Patients should be monitored for hepatotoxicity and managed as recommended in sections&nbsp;4.2 and 4.4.</p><p>&nbsp;</p><p><em>Gastrointestinal effects</em></p><p>Nausea&nbsp;(57%), diarrhoea&nbsp;(54%), vomiting&nbsp;(51%), and constipation&nbsp;(43%) were the most commonly reported all‑causality gastrointestinal events. Most events were mild to moderate in severity. Median times to onset for nausea and vomiting were 3&nbsp;days, and these events declined in frequency after 3&nbsp;weeks of treatment. Supportive care should include the use of antiemetic medicinal products. Median times to onset for diarrhoea and constipation were 13 and 17&nbsp;days, respectively. Supportive care for diarrhoea and constipation should include the use of standard antidiarrhoeal and laxative medicinal products, respectively.</p><p>&nbsp;</p><p>In clinical studies with crizotinib, events of gastrointestinal perforations were reported. There were reports of fatal cases of gastrointestinal perforation during post-marketing use of crizotinib (see section&nbsp;4.4).</p><p>&nbsp;</p><p><em>QT&nbsp;interval prolongation</em></p><p>Across studies in patients with either ALK‑positive or ROS1‑positive advanced NSCLC, QTcF (corrected QT by the Fridericia method) &ge;&nbsp;500&nbsp;msec was recorded in 34&nbsp;(2.1%) of 1619&nbsp;patients with at least 1&nbsp;postbaseline ECG assessment and a maximum increase from baseline in QTcF&nbsp;&ge;&nbsp;60&nbsp;msec was observed in 79&nbsp;(5.0%) of 1585&nbsp;patients with a baseline and at least 1&nbsp;postbaseline ECG assessment. All‑causality Grade&nbsp;3 or 4 Electrocardiogram QT&nbsp;prolonged was reported in 27&nbsp;(1.6%) out of 1722&nbsp;patients (see sections&nbsp;4.2, 4.4, 4.5 and 5.2).</p><p>&nbsp;</p><p>In a single‑arm ECG substudy (see section&nbsp;5.2) using blinded manual ECG&nbsp;measurements 11&nbsp;(21%)&nbsp;patients had an increase from Baseline in QTcF&nbsp;value &ge;&nbsp;30 to &lt;&nbsp;60&nbsp;msec and 1&nbsp;(2%)&nbsp;patient had an increase from Baseline in QTcF&nbsp;value of &ge;&nbsp;60&nbsp;msec. No patients had a maximum QTcF&nbsp;&ge;&nbsp;480&nbsp;msec. The central tendency analysis indicated that the largest mean change from baseline in QTcF was 12.3&nbsp;msec (95%&nbsp;CI 5.1‑19.5 msec, least squares mean [LS] from Analysis of Variance [ANOVA]) and occurred at 6&nbsp;hours post‑dose on Cycle&nbsp;2&nbsp;Day&nbsp;1. All upper limits of the 90%&nbsp;CI for the LS mean change from Baseline in QTcF at all Cycle&nbsp;2&nbsp;Day&nbsp;1 time points were &lt;&nbsp;20&nbsp;msec.</p><p>&nbsp;</p><p>QT&nbsp;prolongation can result in arrhythmias and is a risk factor for sudden death. QT&nbsp;prolongation may clinically manifest as bradycardia, dizziness, and syncope. Electrolyte disturbances, dehydration and bradycardia may further increase the risk of QTc&nbsp;prolongation and thus, periodic monitoring of ECG and electrolyte levels is recommended in patients with GI toxicity (see section&nbsp;4.4).</p><p>&nbsp;</p><p><em>Bradycardia</em></p><p>In studies with crizotinib in patients with either ALK‑positive or ROS1‑positive advanced NSCLC, all‑causality bradycardia was experienced by 219&nbsp;(13%) of 1722&nbsp;patients treated with crizotinib. Most events were mild in severity. A total of 259&nbsp;(16%) of 1666&nbsp;patients with at least 1&nbsp;postbaseline vital sign assessment had a pulse rate &lt;&nbsp;50&nbsp;bpm.</p><p>&nbsp;</p><p>The use of concomitant medicinal products associated with bradycardia should be carefully evaluated. Patients who develop symptomatic bradycardia should be managed as recommended in the Dose Modification and Warnings and Precautions sections (see sections&nbsp;4.2, 4.4 and 4.5).</p><p>&nbsp;</p><p><em>Interstitial lung disease/pneumonitis</em></p><p>Severe, life-threatening, or fatal ILD/pneumonitis can occur in patients treated with crizotinib. Across studies in patients with either ALK‑positive or ROS1‑positive NSCLC (N=1722), 50&nbsp;(3%)&nbsp;patients treated with crizotinib had any grade all‑causality ILD, including 18&nbsp;(1%)&nbsp;patients with Grade&nbsp;3 or 4, and 8&nbsp;(&lt;&nbsp;1%)&nbsp;patients with fatal cases. According to an independent review committee (IRC) assessment of patients with ALK‑positive NSCLC (N=1669), 20&nbsp;(1.2%)&nbsp;patients had ILD/pneumonitis, including 10&nbsp;(&lt;&nbsp;1%)&nbsp;patients with fatal cases. These cases generally occurred within 3&nbsp;months after the initiation of treatment. Patients with pulmonary symptoms indicative of ILD/pneumonitis should be monitored. Other potential causes of ILD/pneumonitis should be excluded (see sections&nbsp;4.2 and 4.4).</p><p>&nbsp;</p><p><em>Visual effects</em></p><p>In clinical studies with crizotinib in patients with either ALK‑positive or ROS1‑positive advanced NSCLC (N=1722), Grade&nbsp;4 visual field defect with vision loss has been reported in 4&nbsp;(0.2%)&nbsp;patients. Optic atrophy and optic nerve disorder have been reported as potential causes of vision loss (see&nbsp;section&nbsp;4.4).</p><p>&nbsp;</p><p>All‑causality, all grade, vision disorder, most commonly visual impairment, photopsia, vision blurred, and vitreous floaters, was experienced by 1084&nbsp;(63%) of 1722&nbsp;patients treated with crizotinib. Of the 1084&nbsp;patients who experienced vision disorder, 95% had events that were mild in severity. Seven (0.4%)&nbsp;patients had temporary treatment discontinuation and 2&nbsp;(0.1%)&nbsp;patients had a dose reduction associated with vision disorder. There were no permanent discontinuations associated with vision disorder for any of the 1722&nbsp;patients treated with crizotinib.</p><p>&nbsp;</p><p>Based on the Visual Symptom Assessment Questionnaire (VSAQ-ALK), patients treated with crizotinib in Study&nbsp;1007 and Study&nbsp;1014 reported a higher incidence of visual disturbances compared to patients treated with chemotherapy. The onset of vision disorders generally started within the first&nbsp;week of medicinal product administration. The majority of patients on the crizotinib arm in randomised Phase&nbsp;3 Studies&nbsp;1007 and 1014 (&gt;&nbsp;50%) reported visual disturbances; which occurred at a frequency of 4 to 7&nbsp;days each week, lasted up to 1&nbsp;minute, and had mild or no impact (scores&nbsp;0 to 3 out of a maximum score of&nbsp;10) on daily activities as captured by the VSAQ-ALK questionnaire.</p><p>&nbsp;</p><p>An ophthalmology substudy using specific ophthalmic assessments at specified time points was conducted in 54&nbsp;patients with NSCLC who received crizotinib 250&nbsp;mg twice daily. Thirty‑eight&nbsp;(70.4%) of the 54&nbsp;patients experienced an Eye Disorders System Organ Class treatment‑emergent all‑causality adverse event of which 30&nbsp;patients had ophthalmic examinations. Of the 30&nbsp;patients, an ophthalmic abnormality of any type was reported in 14&nbsp;(36.8%)&nbsp;patients and no ophthalmic finding was seen in 16&nbsp;(42.1%)&nbsp;patients. The most common findings concerned slit lamp biomicroscopy&nbsp;(21.1%), fundoscopy&nbsp;(15.8%) and visual acuity&nbsp;(13.2%). Pre‑existing ophthalmic abnormalities and concomitant medical conditions which could be contributory to ocular findings were noted in many patients, and no conclusive causal relationship to crizotinib could be determined. There were no findings related to aqueous cell count and anterior chamber aqueous flare assessment. No visual disturbances associated with crizotinib appeared to be related to changes in best corrected visual acuity, the vitreous, the retina, or the optic nerve.</p><p>&nbsp;</p><p>In patients with new onset of Grade&nbsp;4 visual loss, crizotinib treatment should be discontinued and ophthalmological evaluation should be performed. Ophthalmological evaluation is recommended if vision disorder persists or worsens in severity (see sections&nbsp;4.2 and 4.4).</p><p>&nbsp;</p><p><em>Nervous system effects</em></p><p>All‑causality neuropathy, as defined in Table&nbsp;3, was experienced by 435&nbsp;(25%) out of 1722&nbsp;patients treated with crizotinib. Dysgeusia was also very commonly reported in these studies and was primarily Grade&nbsp;1 in severity.</p><p><em><u>&nbsp;</u></em></p><p><em>Renal cyst</em></p><p>All‑causality complex renal cysts were experienced by 52&nbsp;(3%) of 1722&nbsp;patients treated with crizotinib. Local cystic invasion beyond the kidney was observed in some patients. Periodic monitoring with imaging and urinalysis should be considered in patients who develop renal cysts.</p><p>&nbsp;</p><p><em>Neutropenia and leukopenia</em></p><p>Across studies in patients with either ALK‑positive or ROS1‑positive advanced NSCLC (N=1722), Grade&nbsp;3 or 4 neutropenia was observed in 212&nbsp;(12%)&nbsp;patients treated with crizotinib. Median time to onset of any grade neutropenia was 89&nbsp;days. Neutropenia was associated with dose reduction or permanent treatment discontinuation for 3% and &lt;&nbsp;1% of patients, respectively. Less than 0.5% of patients experienced febrile neutropenia in clinical studies with crizotinib.</p><p>&nbsp;</p><p>Across studies in patients with either ALK‑positive or ROS1‑positive advanced NSCLC (N=1722), Grade&nbsp;3 or Grade&nbsp;4 leukopenia was observed in 48&nbsp;(3%)&nbsp;patients treated with crizotinib. Median time to onset of any grade leukopenia was 85&nbsp;days.</p><p>&nbsp;</p><p>Leukopenia was associated with a dose reduction for &lt;&nbsp;0.5% of patients, and no patients permanently discontinued crizotinib treatment associated with leukopenia.</p><p>&nbsp;</p><p>In clinical studies of crizotinib in patients with either ALK‑positive or ROS1‑positive advanced NSCLC, shifts to Grade&nbsp;3 or 4 decreases in leukocytes and neutrophils were observed at frequencies of 4% and 13%, respectively.</p><p>&nbsp;</p><p>Complete blood counts including differential white blood cell counts should be monitored as clinically indicated, with more frequent repeat testing if Grade&nbsp;3 or 4 abnormalities are observed, or if fever or infection occurs. For patients who develop haematologic laboratory abnormalities, see section&nbsp;4.2.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after marketing authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions to National Pharmacovigilance Centre (NPC).</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>To Report side effects</p><p>&nbsp;</p><ul><li><strong>Saudi Arabia</strong></li></ul><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:408px"><tbody><tr><td style="vertical-align:top"><p><strong>National Pharmacovigilance Center (NPC)</strong></p><p>SFDA Call center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa/&nbsp;&nbsp;</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><ul><li><strong>Other GCC States</strong></li></ul><table border="1" cellspacing="0" cellpadding="0" align="left"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of overdose with the medicinal product consists of general supportive measures. There is no antidote for XALKORI.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Anti-neoplastic agents, protein kinase inhibitors; ATC code: L01ED01.</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p>Crizotinib is a selective small‑molecule inhibitor of the ALK receptor tyrosine kinase (RTK) and its oncogenic variants (i.e. ALK fusion events and selected ALK mutations). Crizotinib is also an inhibitor of the Hepatocyte Growth Factor Receptor (HGFR, c-Met) RTK, ROS1 (c-ros) and Recepteur d&rsquo;Origine Nantais (RON) RTK. Crizotinib demonstrated concentration-dependent inhibition of the kinase activity of ALK, ROS1, and c‑Met in biochemical assays and inhibited phosphorylation and modulated kinase-dependent phenotypes in cell‑based assays. Crizotinib demonstrated potent and selective growth inhibitory activity and induced apoptosis in tumour cell lines exhibiting ALK fusion events (including echinoderm microtubule‑associated protein‑like 4 [EML4]‑ALK and nucleophosmin [NPM]‑ALK), ROS1 fusion events, or exhibiting amplification of the <em>ALK</em> or <em>MET</em> gene locus. Crizotinib demonstrated antitumour efficacy, including marked cytoreductive antitumour activity, in mice bearing tumour xenografts that expressed ALK fusion proteins. The antitumour efficacy of crizotinib was dose‑dependent and correlated to pharmacodynamic inhibition of phosphorylation of ALK fusion proteins (including EML4‑ALK and NPM‑ALK) in tumours <em>in vivo</em>. Crizotinib also demonstrated marked antitumour activity in mouse xenograft studies, where tumours were generated using a panel of NIH‑3T3 cell lines engineered to express key ROS1 fusions identified in human tumours. The antitumour efficacy of crizotinib was dose‑dependent and demonstrated a correlation with inhibition of ROS1 phosphorylation <em>in vivo</em>.</p><p>&nbsp;</p><p><u>Clinical studies</u></p><p>&nbsp;</p><p><em>Previously untreated ALK‑positive advanced NSCLC &ndash; randomised Phase&nbsp;3 Study&nbsp;1014</em></p><p>The efficacy and safety of crizotinib for the treatment of patients with ALK‑positive metastatic NSCLC, who had not received previous systemic treatment for advanced disease, were demonstrated in a global, randomised, open‑label Study&nbsp;1014.</p><p>&nbsp;</p><p>The full analysis population included 343&nbsp;patients with ALK‑positive advanced NSCLC as identified by Fluorescence In Situ Hybridisation (FISH) prior to randomisation: 172&nbsp;patients were randomised to crizotinib and 171&nbsp;patients were randomised to chemotherapy (pemetrexed&nbsp;+&nbsp;carboplatin or cisplatin; up to 6&nbsp;cycles of treatment). The demographic and disease characteristics of the overall study population were 62%&nbsp;female, median age of 53&nbsp;years, baseline Eastern Cooperative Oncology Group (ECOG) performance status&nbsp;0 or 1&nbsp;(95%), 51%&nbsp;White and 46%&nbsp;Asian, 4%&nbsp;current smokers, 32%&nbsp;past smokers and 64%&nbsp;never smokers. The disease characteristics of the overall study population were metastatic disease in 98% of patients, 92% of patients&rsquo; tumours were classified as adenocarcinoma histology, and 27% of patients had brain metastases.</p><p>&nbsp;</p><p>Patients could continue crizotinib treatment beyond the time of Response Evaluation Criteria in Solid Tumours (RECIST)‑defined disease progression at the discretion of the investigator if the patient was still experiencing clinical benefit. Sixty‑five of 89&nbsp;(73%)&nbsp;patients treated with crizotinib and 11 of 132&nbsp;(8.3%)&nbsp;patients treated with chemotherapy continued treatment for at least 3&nbsp;weeks after objective disease progression. Patients randomised to chemotherapy could cross over to receive crizotinib upon RECIST‑defined disease progression confirmed by independent radiology review (IRR). One&nbsp;hundred&nbsp;forty‑four&nbsp;(84%)&nbsp;patients in the chemotherapy arm received subsequent crizotinib treatment.</p><p>&nbsp;</p><p>Crizotinib significantly prolonged progression‑free survival (PFS), the primary objective of the study, compared to chemotherapy as assessed by IRR. The PFS benefit of crizotinib was consistent across subgroups of baseline patient characteristics such as age, gender, race, smoking class, time since diagnosis, ECOG performance status, and presence of brain metastases. There was a numerical improvement in overall survival (OS) in the patients treated with crizotinib, although this improvement was not statistically significant. Efficacy data from randomised Phase&nbsp;3 Study&nbsp;1014 are summarised in Table&nbsp;4, and the Kaplan‑Meier curves for PFS and OS are shown in Figure&nbsp;1 and 2, respectively.</p><p><u>&nbsp;</u></p><p><strong>Table&nbsp;4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Efficacy results from randomised Phase&nbsp;3 Study&nbsp;1014 (full analysis population) in patients with previously untreated ALK-positive advanced NSCLC*</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Response parameter</strong></p></td><td style="vertical-align:top"><p><strong>Crizotinib</strong></p><p><strong>N=172</strong></p></td><td style="vertical-align:top"><p><strong>Chemotherapy</strong></p><p><strong>N=171</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Progression-free survival (based on IRR)</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Number with event, n (%)</p></td><td style="vertical-align:top"><p>100 (58%)</p></td><td style="vertical-align:top"><p>137 (80%)</p></td></tr><tr><td style="vertical-align:top"><p>Median PFS in months (95%&nbsp;CI)</p></td><td style="vertical-align:top"><p>10.9 (8.3, 13.9)</p></td><td style="vertical-align:top"><p>7.0<sup>a</sup> (6.8, 8.2)</p></td></tr><tr><td style="vertical-align:top"><p>HR<sup> </sup>(95%&nbsp;CI)<sup>b</sup></p></td><td colspan="2" style="vertical-align:top"><p>0.45<sup> </sup>(0.35, 0.60)</p></td></tr><tr><td style="vertical-align:top"><p>p‑value<sup>c</sup></p></td><td colspan="2" style="vertical-align:top"><p>&lt;&nbsp;0.0001</p></td></tr><tr><td style="vertical-align:top"><p><strong>Overall survival</strong><sup>d</sup></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number of deaths, n (%)</p></td><td style="vertical-align:top"><p>71 (41%)</p></td><td style="vertical-align:top"><p>81 (47%)</p></td></tr><tr><td style="vertical-align:top"><p>Median OS in months (95%&nbsp;CI)</p></td><td style="vertical-align:top"><p>NR (45.8, NR)</p></td><td style="vertical-align:top"><p>47.5 (32.2, NR)</p></td></tr><tr><td style="vertical-align:top"><p>HR&nbsp;(95%&nbsp;CI)<sup>b</sup></p></td><td colspan="2" style="vertical-align:top"><p>0.76 (0.55, 1.05)</p></td></tr><tr><td style="vertical-align:top"><p>p‑value<sup>c</sup></p></td><td colspan="2" style="vertical-align:top"><p>0.0489</p></td></tr><tr><td style="vertical-align:top"><p>12‑Month survival probability,<sup>d</sup> %&nbsp;(95%&nbsp;CI)</p></td><td style="vertical-align:top"><p>83.5 (77.0, 88.3)</p></td><td style="vertical-align:top"><p>78.4 (71.3, 83.9)</p></td></tr><tr><td style="vertical-align:top"><p>18‑Month survival probability,<sup>d</sup> %&nbsp;(95%&nbsp;CI)</p></td><td style="vertical-align:top"><p>71.5 (64.0, 77.7)</p></td><td style="vertical-align:top"><p>66.6 (58.8, 73.2)</p></td></tr><tr><td style="vertical-align:top"><p>48‑Month survival probability,<sup>d</sup> %&nbsp;(95%&nbsp;CI)</p></td><td style="vertical-align:top"><p>56.6 (48.3, 64.1)</p></td><td style="vertical-align:top"><p>49.1 (40.5, 57.1)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Objective response rate (based on IRR)</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Objective response rate %&nbsp;(95%&nbsp;CI)</p></td><td style="vertical-align:top"><p>74% (67, 81)</p></td><td style="vertical-align:top"><p>45%<sup>e</sup> (37, 53)</p></td></tr><tr><td style="vertical-align:top"><p>p‑value<sup>f</sup></p></td><td colspan="2" style="vertical-align:top"><p>&lt;&nbsp;0.0001</p></td></tr><tr><td style="vertical-align:top"><p><strong>Duration of response</strong></p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Months<sup>g</sup> (95%&nbsp;CI)</p></td><td style="vertical-align:top"><p>11.3 (8.1, 13.8)</p></td><td style="vertical-align:top"><p>5.3 (4.1, 5.8)</p></td></tr></tbody></table><p>Abbreviations: CI=confidence interval; HR=hazard ratio; IRR=independent radiology review; N/n=number of patients; NR=not reached; PFS=progression‑free survival; ORR=objective response rate; OS=overall survival.</p><p>*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PFS, objective response rate and duration of response are based on the data cutoff date of 30&nbsp;November&nbsp;2013; OS is based on the last patient last visit date of 30&nbsp;November&nbsp;2016, and is based on a median follow up of approximately 46&nbsp;months.</p><p>a.&nbsp;&nbsp; Median PFS times were 6.9&nbsp;months (95%&nbsp;CI: 6.6, 8.3) for pemetrexed/cisplatin (HR=0.49; p‑value&nbsp;&lt;&nbsp;0.0001 for crizotinib compared with pemetrexed/cisplatin) and 7.0&nbsp;months (95%&nbsp;CI: 5.9, 8.3) for pemetrexed/carboplatin (HR=0.45; p‑value&nbsp;&lt;&nbsp;0.0001 for crizotinib compared with pemetrexed/carboplatin).</p><p>b. &nbsp; Based on the Cox proportional hazards stratified analysis.</p><p>c. &nbsp; Based on the stratified log‑rank test (1‑sided).</p><p>d. &nbsp; Updated based on final OS analysis. OS analysis was not adjusted for the potentially confounding effects of cross over (144&nbsp;[84%]&nbsp;patients in the chemotherapy arm received subsequent crizotinib treatment).</p><p>e.&nbsp;&nbsp; ORRs were 47%&nbsp;(95%&nbsp;CI: 37, 58) for pemetrexed/cisplatin (p‑value&nbsp;&lt;&nbsp;0.0001 compared with crizotinib) and 44%&nbsp;(95%&nbsp;CI: 32, 55) for pemetrexed/carboplatin (p‑value&nbsp;&lt;&nbsp;0.0001 compared with crizotinib).</p><p>f. &nbsp;&nbsp; Based on the stratified Cochran‑Mantel‑Haenszel test (2‑sided).</p><p>g.&nbsp;&nbsp; Estimated using the Kaplan‑Meier method.</p><p>&nbsp;</p><p><strong>Figure&nbsp;1.&nbsp;&nbsp;&nbsp;&nbsp; Kaplan-Meier curves for progression-free survival (based on IRR) by treatment arm in randomised Phase&nbsp;3 Study&nbsp;1014 (full analysis population) in patients with previously untreated ALK-positive advanced NSCLC</strong></p><p><!--[if gte vml 1]><v:shapetype id="_x0000_t75"
 coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
 filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_1" o:spid="_x0000_i1027" type="#_x0000_t75"
 style='width:454.5pt;height:208.5pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/Bakhsm/AppData/Local/Temp/1/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="606" height="278" src="file:///C:/Users/Bakhsm/AppData/Local/Temp/1/msohtmlclip1/01/clip_image002.gif" /></p><p>Abbreviations: CI=confidence interval; N=number of patients; p=p‑value.</p><p><!--[if gte vml 1]><o:wrapblock><v:shape
  id="Picture_x0020_1" o:spid="_x0000_s1026" type="#_x0000_t75" style='position:absolute;
  left:0;text-align:left;margin-left:5.7pt;margin-top:50.4pt;width:453.3pt;
  height:256.05pt;z-index:251657728;visibility:visible;mso-wrap-style:square;
  mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:9pt;
  mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
  mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
  mso-position-horizontal-relative:text;mso-position-vertical:absolute;
  mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
  mso-width-relative:page;mso-height-relative:page'>
  <v:imagedata src="file:///C:/Users/Bakhsm/AppData/Local/Temp/1/msohtmlclip1/01/clip_image003.png"
   o:title=""/>
  <w:wrap type="topAndBottom"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="604" height="341" src="file:///C:/Users/Bakhsm/AppData/Local/Temp/1/msohtmlclip1/01/clip_image004.jpg" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--><br /><strong>Figure&nbsp;2. &nbsp;&nbsp;&nbsp; Kaplan-Meier curves for overall survival by treatment arm in randomised Phase&nbsp;3 Study&nbsp;1014 (full analysis population) in patients with previously untreated ALK‑positive advanced NSCLC</strong></p><p>&nbsp;</p><p>Abbreviations: CI=confidence interval; N=number of patients; p=p‑value.</p><p>&nbsp;</p><p>For patients with previously treated baseline brain metastases, the median intracranial time to progression (IC‑TTP) was 15.7&nbsp;months in the crizotinib arm (N=39) and 12.5&nbsp;months in the chemotherapy arm (N=40) (HR=0.45&nbsp;[95%&nbsp;CI: 0.19, 1.07]; 1‑sided p‑value=0.0315). For patients without baseline brain metastases, the median IC‑TTP was not reached in either the crizotinib (N=132) or the chemotherapy arms (N=131)&nbsp;(HR=0.69 [95%&nbsp;CI: 0.33, 1.45]; 1‑sided p‑value=0.1617).</p><p>&nbsp;</p><p>Patient‑reported symptoms and global&nbsp;QOL were collected using the EORTC QLQ‑C30 and its lung cancer module (EORTC QLQ‑LC13). A total of 166&nbsp;patients in the crizotinib arm and 163&nbsp;patients in the chemotherapy arm had completed the EORTC QLQ‑C30 and LC13 questionnaires at baseline and at least 1&nbsp;postbaseline visit. Significantly greater improvement in global&nbsp;QOL was observed in the crizotinib arm compared to the chemotherapy arm (overall difference in change from baseline scores&nbsp;13.8; p‑value&nbsp;&lt;&nbsp;0.0001).</p><p>&nbsp;</p><p>Time to Deterioration (TTD) was prespecified as the first occurrence of a &ge;&nbsp;10‑point increase in scores from baseline in symptoms of pain in chest, cough, or dyspnoea as assessed by EORTC QLQ‑LC13.</p><p>&nbsp;</p><p>Crizotinib resulted in symptom benefits by significantly prolonging TTD compared to chemotherapy (median 2.1&nbsp;months versus 0.5&nbsp;months; HR=0.59; 95%&nbsp;CI: 0.45, 0.77; Hochberg‑adjusted log‑rank 2‑sided p‑value&nbsp;=0.0005).</p><p><u>&nbsp;</u></p><p><em>Previously treated ALK‑positive advanced NSCLC&nbsp;&ndash;&nbsp;randomised Phase&nbsp;3 Study&nbsp;1007</em></p><p>The efficacy and safety of crizotinib for the treatment of patients with ALK‑positive metastatic NSCLC, who had received previous systemic treatment for advanced disease, were demonstrated in a global, randomised, open‑label Study&nbsp;1007.</p><p>&nbsp;</p><p>The full analysis population included 347&nbsp;patients with ALK‑positive advanced NSCLC as identified by FISH prior to randomisation. One&nbsp;hundred&nbsp;seventy‑three&nbsp;(173)&nbsp;patients were randomised to crizotinib and 174&nbsp;patients were randomised to chemotherapy (either pemetrexed or docetaxel). The demographic and disease characteristics of the overall study population were 56%&nbsp;female, median age of 50&nbsp;years, baseline ECOG performance status&nbsp;0&nbsp;(39%) or 1&nbsp;(52%), 52%&nbsp;White and 45%&nbsp;Asian, 4%&nbsp;current smokers, 33%&nbsp;past smokers, and 63%&nbsp;never smokers, 93% metastatic, and 93% of patients&#39; tumours were classified as adenocarcinoma histology.</p><p>&nbsp;</p><p>Patients could continue treatment as assigned beyond the time of RECIST‑defined disease progression at the discretion of the investigator if the patient was perceived to be experiencing clinical benefit. Fifty‑eight of 84&nbsp;(69%)&nbsp;patients treated with crizotinib and 17 of 119&nbsp;(14%)&nbsp;patients treated with chemotherapy continued treatment for at least 3&nbsp;weeks after objective disease progression. Patients randomised to chemotherapy could crossover to receive crizotinib upon RECIST‑defined disease progression confirmed by IRR.</p><p>&nbsp;</p><p>Crizotinib significantly prolonged PFS, the primary objective of the study, compared to chemotherapy as assessed by IRR. The PFS benefit of crizotinib was consistent across subgroups of baseline patient characteristics such as age, gender, race, smoking class, time since diagnosis, ECOG performance status, presence of brain metastases and prior EGFR&nbsp;TKI&nbsp;therapy.</p><p>&nbsp;</p><p>Efficacy data from Study&nbsp;1007 are summarised in Table&nbsp;5, and the Kaplan‑Meier curves for PFS and OS are shown in Figure&nbsp;3 and 4, respectively.</p><p>&nbsp;</p><p><strong>Table&nbsp;5. Efficacy results from randomised Phase&nbsp;3 Study&nbsp;1007 (full analysis population) </strong><strong>in patients with previously treated ALK-positive advanced NSCLC*</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:top"><p>Response parameter</p></td><td style="vertical-align:top"><p>Crizotinib</p><p>N=173</p></td><td style="vertical-align:top"><p>Chemotherapy</p><p>N=174</p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong>Progression-free survival (based on IRR)</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Number with event, n (%)</p></td><td style="vertical-align:top"><p>100 (58%)</p></td><td style="vertical-align:top"><p>127 (73%)</p></td></tr><tr><td style="vertical-align:top"><p>Type of event, n (%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Progressive disease</p></td><td style="vertical-align:top"><p>84 (49%)</p></td><td style="vertical-align:top"><p>119 (68%)</p></td></tr><tr><td style="vertical-align:top"><p>Death without objective progression</p></td><td style="vertical-align:top"><p>16 (9%)</p></td><td style="vertical-align:top"><p>8 (5%)</p></td></tr><tr><td style="vertical-align:top"><p>Median PFS in months (95%&nbsp;CI)</p></td><td style="vertical-align:top"><p>7.7 (6.0, 8.8)</p></td><td style="vertical-align:top"><p>3.0<sup>a</sup> (2.6, 4.3)</p></td></tr><tr><td style="vertical-align:top"><p>HR<sup> </sup>(95%&nbsp;CI)<sup>b</sup></p></td><td colspan="2" style="vertical-align:top"><p>0.49<sup> </sup>(0.37, 0.64)</p></td></tr><tr><td style="vertical-align:top"><p>p‑value<sup>c</sup></p></td><td colspan="2" style="vertical-align:top"><p>&lt;&nbsp;0.0001</p></td></tr><tr><td style="vertical-align:top"><p><strong>Overall survival<sup>d</sup></strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number of deaths, n (%)</p></td><td style="vertical-align:top"><p>116 (67%)</p></td><td style="vertical-align:top"><p>126 (72%)</p></td></tr><tr><td style="vertical-align:top"><p>Median OS in months (95%&nbsp;CI)</p></td><td style="vertical-align:top"><p>21.7 (18.9, 30.5)</p></td><td style="vertical-align:top"><p>21.9 (16.8, 26.0)</p></td></tr><tr><td style="vertical-align:top"><p>HR (95%&nbsp;CI)<sup>b</sup></p></td><td colspan="2" style="vertical-align:top"><p>0.85 (0.66, 1.10)</p></td></tr><tr><td style="vertical-align:top"><p>p‑value<sup>c</sup></p></td><td colspan="2" style="vertical-align:top"><p>0.1145</p></td></tr><tr><td style="vertical-align:top"><p>6-Month survival probability,<sup>e</sup> %&nbsp;(95%&nbsp;CI)</p></td><td style="vertical-align:top"><p>86.6 (80.5, 90.9)</p></td><td style="vertical-align:top"><p>83.8 (77.4, 88.5)</p></td></tr><tr><td style="vertical-align:top"><p>1-Year survival probability,<sup>e</sup> %&nbsp;(95%&nbsp;CI)</p></td><td style="vertical-align:top"><p>70.4 (62.9, 76.7)</p></td><td style="vertical-align:top"><p>66.7 (59.1, 73.2)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Objective response rate (based on IRR)</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Objective response rate %&nbsp;(95%&nbsp;CI)</p></td><td style="vertical-align:top"><p>65% (58, 72)</p></td><td style="vertical-align:top"><p>20%<sup>f</sup> (14, 26)</p></td></tr><tr><td style="vertical-align:top"><p>p‑value<sup>g</sup></p></td><td colspan="2" style="vertical-align:top"><p>&lt;&nbsp;0.0001</p></td></tr><tr><td style="vertical-align:top"><p><strong>Duration of response</strong></p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Median<sup>e</sup>, months (95%&nbsp;CI)</p></td><td style="vertical-align:top"><p>7.4 (6.1, 9.7)</p></td><td style="vertical-align:top"><p>5.6 (3.4, 8.3)</p></td></tr></tbody></table><p>Abbreviations: CI=confidence interval; HR=hazard ratio; IRR=independent radiology review; N/n=number of patients; PFS=progression-free survival; ORR=objective response rate; OS=overall survival.</p><p>*&nbsp;&nbsp;&nbsp; PFS, objective response rate and duration of response are based on the data cutoff date of 30&nbsp;March&nbsp;2012; OS is based on the data cutoff date of 31&nbsp;August&nbsp;2015.</p><p>a. The median PFS times were 4.2&nbsp;months (95%&nbsp;CI: 2.8, 5.7) for pemetrexed (HR=0.59; p‑value=0.0004 for crizotinib compared with pemetrexed) and 2.6&nbsp;months (95%&nbsp;CI: 1.6, 4.0) for docetaxel (HR=0.30;&nbsp;p‑value&nbsp;&lt;&nbsp;0.0001 for crizotinib compared with docetaxel).</p><p>b. Based on the Cox proportional hazards stratified analysis.</p><p>c. Based on the stratified log‑rank test (1‑sided).</p><p>d. &nbsp;&nbsp;&nbsp; Updated based on final OS analysis. Final OS analysis was not adjusted for the potentially confounding effects of crossover (154&nbsp;[89%]&nbsp;patients received subsequent crizotinib treatment).</p><p>e. Estimated using the Kaplan‑Meier method.</p><p>f.&nbsp; ORRs were 29%&nbsp;(95%&nbsp;CI: 21, 39) for pemetrexed (p‑value&nbsp;&lt;&nbsp;0.0001 compared with crizotinib) and 7%&nbsp;(95%&nbsp;CI: 2, 16) for docetaxel (p‑value&nbsp;&lt;&nbsp;0.0001 compared with crizotinib).</p><p>g. Based on the stratified Cochran‑Mantel‑Haenszel test (2‑sided).</p><p>&nbsp;</p><p><strong>Figure&nbsp;3.&nbsp;&nbsp;&nbsp;&nbsp; Kaplan-Meier curves for progression-free survival (based on IRR) by treatment arm in randomised Phase&nbsp;3 Study&nbsp;1007 (full analysis population) in patients with previously treated ALK-positive advanced NSCLC</strong></p><p>&nbsp;<!--[if gte vml 1]><v:shape
 id="Picture_x0020_2" o:spid="_x0000_i1026" type="#_x0000_t75" style='width:411pt;
 height:270.75pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/Bakhsm/AppData/Local/Temp/1/msohtmlclip1/01/clip_image005.png"
  o:title="" croptop="6510f"/>
</v:shape><![endif]--><img width="548" height="361" src="file:///C:/Users/Bakhsm/AppData/Local/Temp/1/msohtmlclip1/01/clip_image006.jpg" /></p><p>Abbreviations: CI=confidence interval; N=number of patients; p=p‑value.</p><p>&nbsp;</p><p><strong>Figure&nbsp;4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Kaplan-Meier curves for overall survival by treatment arm in randomised Phase&nbsp;3 Study&nbsp;1007 (full analysis population) in patients with previously treated ALK‑positive advanced NSCLC</strong></p><p><!--[if gte vml 1]><v:shape id="Picture_x0020_6" o:spid="_x0000_i1025"
 type="#_x0000_t75" style='width:453.75pt;height:248.25pt;visibility:visible;
 mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/Bakhsm/AppData/Local/Temp/1/msohtmlclip1/01/clip_image007.png"
  o:title=""/>
</v:shape><![endif]--><img width="605" height="331" src="file:///C:/Users/Bakhsm/AppData/Local/Temp/1/msohtmlclip1/01/clip_image008.gif" /></p><p>Abbreviations: CI=confidence interval; N=number of patients; p=p‑value.</p><p>&nbsp;</p><p>Fifty‑two&nbsp;(52)&nbsp;patients treated with crizotinib and 57&nbsp;chemotherapy‑treated patients with previously treated or untreated asymptomatic brain metastases were enrolled in randomised Phase&nbsp;3&nbsp;Study&nbsp;1007. Intracranial Disease Control Rate (IC‑DCR) at 12&nbsp;weeks was 65% and 46% for crizotinib and chemotherapy‑treated patients, respectively.</p><p>&nbsp;</p><p>Patient-reported symptoms and global&nbsp;QOL were collected using the EORTC QLQ‑C30 and its lung cancer module (EORTC QLQ‑LC13) at baseline (Day&nbsp;1 Cycle&nbsp;1) and Day&nbsp;1 of each subsequent treatment cycle. A total of 162&nbsp;patients in the crizotinib arm and 151&nbsp;patients in the chemotherapy arm had completed the EORTC QLQ‑C30 and LC13 questionnaires at baseline and at least 1&nbsp;postbaseline visit.</p><p>&nbsp;</p><p>Crizotinib resulted in symptoms benefit by significantly prolonging time to deterioration (median 4.5&nbsp;months versus 1.4&nbsp;months) in patients who reported symptoms of pain in chest, dyspnoea, or cough, compared to chemotherapy (HR&nbsp;0.50; 95%&nbsp;CI: 0.37, 0.66; Hochberg‑adjusted log‑rank p&nbsp;&lt;&nbsp;0.0001).</p><p>&nbsp;</p><p>Crizotinib showed a significantly greater improvement from baseline compared to chemotherapy in alopecia (Cycles&nbsp;2 to 15; p‑value&nbsp;&lt;&nbsp;0.05), cough (Cycles&nbsp;2 to 20; p‑value&nbsp;&lt;&nbsp;0.0001), dyspnoea (Cycles&nbsp;2 to 20; p‑value&nbsp;&lt;&nbsp;0.0001), haemoptysis (Cycles&nbsp;2 to 20; p‑value&nbsp;&lt;&nbsp;0.05), pain in arm or shoulder (Cycles&nbsp;2 to 20; p‑value&nbsp;&lt;&nbsp;0.0001), pain in chest (Cycles&nbsp;2 to 20; p‑value&nbsp;&lt;&nbsp;0.0001), and pain in other parts (Cycles&nbsp;2 to 20; p‑value&nbsp;&lt;&nbsp;0.05). Crizotinib resulted in a significantly lower deterioration from baseline in peripheral neuropathy (Cycles&nbsp;6 to 20; p‑value&nbsp;&lt;&nbsp;0.05), dysphagia (Cycles&nbsp;5 to 11; p‑value&nbsp;&lt;&nbsp;0.05) and sore mouth (Cycle&nbsp;2 to 20; p‑value&nbsp;&lt;&nbsp;0.05) compared to chemotherapy.</p><p>&nbsp;</p><p>Crizotinib resulted in overall global quality of life benefits with a significantly greater improvement from baseline observed in the crizotinib arm compared to the chemotherapy arm (Cycles&nbsp;2 to 20; p‑value&nbsp;&lt;&nbsp;0.05).</p><p>&nbsp;</p><p><em>Single‑arm studies in ALK‑positive advanced NSCLC</em></p><p>The use of single‑agent crizotinib in the treatment of ALK‑positive advanced NSCLC was investigated in 2&nbsp;multinational, single‑arm studies (Studies&nbsp;1001 and 1005). Of the patients enrolled in these studies, the patients described below had received prior systemic therapy for locally advanced or metastatic disease. The primary efficacy endpoint in both studies was objective response rate (ORR) according to RECIST.</p><p>&nbsp;</p><p>A total of 149&nbsp;ALK‑positive advanced NSCLC patients, including 125&nbsp;patients with previously treated ALK‑positive advanced NSCLC, were enrolled into Study&nbsp;1001 at the time of data cutoff for PFS and ORR analysis. The demographic and disease characteristics were 50%&nbsp;female, median age of 51&nbsp;years, baseline ECOG performance status of 0&nbsp;(32%) or 1&nbsp;(55%), 61%&nbsp;White and 30%&nbsp;Asian, less than 1%&nbsp;were current smokers, 27%&nbsp;former smokers, 72%&nbsp;never smokers, 94%&nbsp;metastatic, and 98% of the cancers were classified as adenocarcinoma histology. The median duration of treatment was 42&nbsp;weeks.</p><p>&nbsp;</p><p>A total of 934&nbsp;patients with ALK‑positive advanced NSCLC were treated with crizotinib in Study&nbsp;1005 at the time of data cutoff for PFS and ORR analysis. The demographic and disease characteristics were 57%&nbsp;female, median age of 53&nbsp;years, baseline ECOG performance status of 0/1&nbsp;(82%) or 2/3&nbsp;(18%), 52%&nbsp;White and 44%&nbsp;Asian, 4%&nbsp;current smokers, 30%&nbsp;former smokers, 66%&nbsp;never smokers, 92%&nbsp;metastatic, and 94% of the cancers were classified as adenocarcinoma histology. The median duration of treatment for these patients was 23&nbsp;weeks. Patients could continue treatment beyond the time of RECIST‑defined disease progression at the discretion of the investigator. Seventy‑seven of 106&nbsp;patients (73%) continued crizotinib treatment for at least 3&nbsp;weeks after objective disease progression.</p><p>&nbsp;</p><p>Efficacy data from Studies&nbsp;1001 and 1005 are provided in Table&nbsp;6.</p><p>&nbsp;</p><p><strong>Table&nbsp;6: ALK-positive advanced NSCLC efficacy results from Studies&nbsp;1001 and 1005</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td><p><strong>Efficacy parameter</strong></p></td><td style="vertical-align:top"><p><strong>Study&nbsp;1001</strong></p></td><td style="vertical-align:top"><p><strong>Study&nbsp;1005</strong></p></td></tr></thead><tbody><tr><td><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>N=125<sup>a</sup></strong></p></td><td style="vertical-align:top"><p><strong>N=765<sup>a</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Objective response rate<sup>b</sup> [% (95%&nbsp;CI)]</p></td><td style="vertical-align:top"><p>60 (51, 69)</p></td><td style="vertical-align:top"><p>48 (44, 51)</p></td></tr><tr><td style="vertical-align:top"><p>Time to tumour response [median (range)] weeks</p></td><td style="vertical-align:top"><p>7.9 (2.1, 39.6)</p></td><td style="vertical-align:top"><p>6.1 (3, 49)</p></td></tr><tr><td style="vertical-align:top"><p>Duration of response<sup>c</sup> [median (95%&nbsp;CI)] weeks</p></td><td style="vertical-align:top"><p>48.1 (35.7, 64.1)</p></td><td style="vertical-align:top"><p>47.3 (36, 54)</p></td></tr><tr><td style="vertical-align:top"><p>Progression‑free survival<sup>c</sup> [median (95%&nbsp;CI)] months</p></td><td style="vertical-align:top"><p>9.2 (7.3, 12.7)</p></td><td style="vertical-align:top"><p>7.8 (6.9, 9.5)<sup>d</sup></p></td></tr><tr><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p><strong>N=154<sup>e</sup></strong></p></td><td style="vertical-align:bottom"><p><strong>N=905<sup>e</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Number of deaths, n (%)</p></td><td style="vertical-align:top"><p>83 (54%)</p></td><td style="vertical-align:top"><p>504 (56%)</p></td></tr><tr><td style="vertical-align:top"><p>Overall survival<sup>c</sup> [median (95%&nbsp;CI)] months</p></td><td style="vertical-align:top"><p>28.9 (21.1, 40.1)</p></td><td style="vertical-align:top"><p>21.5 (19.3, 23.6)</p></td></tr></tbody></table><p>Abbreviations: CI=confidence interval; N/n=number of patients; PFS=progression-free survival.</p><p>a. Per data cutoff dates 01&nbsp;June&nbsp;2011 (Study&nbsp;1001) and 15&nbsp;February&nbsp;2012 (Study&nbsp;1005).</p><p>b. Three&nbsp;patients were not evaluable for response in Study&nbsp;1001, and 42&nbsp;patients were not evaluable for response in Study&nbsp;1005.</p><p>c. Estimated using the Kaplan‑Meier method.</p><p>d. PFS data from Study&nbsp;1005 included 807&nbsp;patients in the safety analysis population who were identified by the FISH assay (data cutoff date 15&nbsp;February&nbsp;2012).</p><p>e. Per data cutoff date 30&nbsp;November&nbsp;2013.</p><p>&nbsp;</p><p><em>ROS1‑positive advanced NSCLC</em></p><p>The use of single‑agent crizotinib in the treatment of ROS1‑positive advanced NSCLC was investigated in multicenter, multinational, single‑arm Study&nbsp;1001. A total of 53&nbsp;ROS1‑positive advanced NSCLC patients were enrolled in the study at the time of data cutoff, including 46&nbsp;patients with previously treated ROS1‑positive advanced NSCLC and a limited number of patients (N=7) who had no prior systemic treatment. The primary efficacy endpoint was ORR according to RECIST. Secondary endpoints included time to tumour response (TTR), duration of response (DR), PFS, and OS. Patients received crizotinib 250&nbsp;mg orally twice daily.</p><p>&nbsp;</p><p>The demographic characteristics were 57%&nbsp;female; median age 55&nbsp;years; baseline ECOG performance status of 0 or 1&nbsp;(98%) or 2&nbsp;(2%), 57%&nbsp;White and 40%&nbsp;Asian; 25%&nbsp;former smokers, and 75%&nbsp;never smokers. The disease characteristics were 94%&nbsp;metastatic, 96%&nbsp;adenocarcinoma histology, and 13% with no prior systemic therapy for metastatic disease.</p><p>&nbsp;</p><p>In Study&nbsp;1001, patients were required to have advanced ROS1‑positive advanced NSCLC prior to entering the clinical study. For most patients, ROS1‑positive NSCLC was identified by FISH. The median duration of treatment was 22.4&nbsp;months (95%&nbsp;CI: 15.0, 35.9). There were 6&nbsp;complete responses and 32&nbsp;partial responses for an ORR of 72%&nbsp;(95%&nbsp;CI:&nbsp;58%,&nbsp;83%). The median DR was 24.7&nbsp;months (95%&nbsp;CI: 15.2, 45.3). Fifty&nbsp;percent of objective tumour responses were achieved during the first 8&nbsp;weeks of treatment. The median PFS at the time of data cutoff was 19.3&nbsp;months (95%&nbsp;CI: 15.2, 39.1). The median OS at the time of data cutoff was 51.4&nbsp;months (95%&nbsp;CI: 29.3, NR).</p><p>&nbsp;</p><p>Efficacy data from ROS1‑positive advanced NSCLC patients from Study&nbsp;1001 are provided in Table&nbsp;7.</p><p>&nbsp;</p><p><strong>Table&nbsp;7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ROS1-positive advanced NSCLC efficacy results from Study&nbsp;1001</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td><p><strong>Efficacy parameter</strong></p></td><td style="vertical-align:top"><p><strong>Study&nbsp;1001</strong></p><p><strong>N=53<sup>a</sup></strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Objective response rate [% (95%&nbsp;CI)]</p></td><td style="vertical-align:top"><p>72 (58, 83)</p></td></tr><tr><td style="vertical-align:top"><p>Time to tumour response [median (range)] weeks</p></td><td style="vertical-align:top"><p>8 (4, 104)</p></td></tr><tr><td style="vertical-align:top"><p>Duration of response<sup>b</sup> [median (95%&nbsp;CI)] months</p></td><td style="vertical-align:top"><p>24.7 (15.2, 45.3)</p></td></tr><tr><td style="vertical-align:top"><p>Progression‑free survival<sup>b</sup> [median (95%&nbsp;CI)] months</p></td><td style="vertical-align:top"><p>19.3 (15.2, 39.1)</p></td></tr><tr><td style="vertical-align:top"><p>OS<sup>b</sup> [median (95%&nbsp;CI)] months</p></td><td style="vertical-align:top"><p>51.4 (29.3, NR)</p></td></tr></tbody></table><p>Abbreviations: CI=confidence interval; N=number of patients; NR=not reached; OS=overall survival.</p><p>OS is based on a median follow up of approximately 63&nbsp;months.</p><p>a. &nbsp; Per data cutoff date30&nbsp;June&nbsp;2018.</p><p>b. &nbsp; Estimated using the Kaplan‑Meier method.</p><p>&nbsp;</p><p><u>Non‑adenocarcinoma histology</u></p><p><u>&nbsp;</u></p><p>Twenty‑one&nbsp;patients with previously untreated and 12&nbsp;patients with previously treated advanced ALK‑positive non-adenocarcinoma histology NSCLC were enrolled in randomised Phase&nbsp;3&nbsp;Studies&nbsp;1014 and 1007, respectively. The subgroups in these studies were too small to draw reliable conclusions. Of note, no patients with SCC histology were randomised in the crizotinib arm in Study&nbsp;1007 and no patients with SCC were enrolled in Study&nbsp;1014 due to pemetrexed‑based regimen being used as a comparator.</p><p>&nbsp;</p><p>Information is available from 45&nbsp;response‑evaluable patients with previously treated non‑adenocarcinoma NSCLC (including 22&nbsp;patients with SCC) in Study&nbsp;1005. Partial responses were observed in 20 of 45&nbsp;patients with non‑adenocarcinoma NSCLC for an ORR of 44%, and 9&nbsp;of&nbsp;22&nbsp;patients with SCC NSCLC for an ORR of 41%, both of which were less than the ORR reported in Study&nbsp;1005&nbsp;(54%) for all patients.</p><p>&nbsp;</p><p><u>Re‑treatment with crizotinib</u></p><p><u>&nbsp;</u></p><p>No safety and efficacy data are available on re-treatment with crizotinib of patients who received crizotinib in previous lines of therapy.</p><p>&nbsp;</p><p><u>Elderly</u></p><p><u>&nbsp;</u></p><p>Of 171&nbsp;ALK‑positive NSCLC patients treated with crizotinib in randomised Phase&nbsp;3 Study&nbsp;1014, 22&nbsp;(13%) were 65&nbsp;years or older, and of 109&nbsp;ALK‑positive patients treated with crizotinib who crossed over from chemotherapy arm, 26&nbsp;(24%) were 65&nbsp;years or older. Of 172&nbsp;ALK‑positive patients treated with crizotinib in randomised Phase&nbsp;3 Study&nbsp;1007, 27&nbsp;(16%) were 65&nbsp;years or older. Of 154 and 1063&nbsp;ALK‑positive NSCLC patients in single arm Studies&nbsp;1001 and 1005, 22&nbsp;(14%) and 173&nbsp;(16%) were 65&nbsp;years or older, respectively. In ALK‑positive NSCLC patients, the frequency of adverse reactions was generally similar for patients &lt;&nbsp;65&nbsp;years of age and patients &ge;&nbsp;65&nbsp;years of age with the exception of oedema and constipation, which were reported with greater frequency (&ge;&nbsp;15% difference) in Study&nbsp;1014 among patients treated with crizotinib &ge;&nbsp;65&nbsp;years of age. No patients in the crizotinib arm of randomised Phase&nbsp;3 Studies&nbsp;1007 and 1014, and single‑arm Study&nbsp;1005 were &gt;&nbsp;85&nbsp;years. There was one&nbsp;ALK‑positive patient &gt;&nbsp;85&nbsp;years old out of 154&nbsp;patients in single-arm Study&nbsp;1001 (see also section&nbsp;4.2 and 5.2). Of the 53&nbsp;ROS1‑positive NSCLC patients in single‑arm Study&nbsp;1001, 15&nbsp;(28%) were 65&nbsp;years or older. There were no ROS1‑positive patients &gt;&nbsp;85&nbsp;years old in Study&nbsp;1001.</p><p><u>&nbsp;</u></p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>The European Medicines Agency has waived the obligation to submit the results of studies with XALKORI in all subsets of the paediatric population in NSCLC<em> </em>(see section&nbsp;4.2 for information on paediatric use).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong></p><p><u>Absorption</u></p><p><u>&nbsp;</u></p><p>Following oral single dose administration in the fasted state, crizotinib is absorbed with median time to achieve peak concentrations of 4 to 6&nbsp;hours. With twice daily dosing, steady‑state was achieved within 15&nbsp;days. The absolute bioavailability of crizotinib was determined to be 43% following the administration of a single 250&nbsp;mg oral dose.</p><p>&nbsp;</p><p>A high‑fat meal reduced crizotinib AUC<sub>inf</sub> and C<sub>max</sub> by approximately 14% when a 250&nbsp;mg single dose was given to healthy volunteers. Crizotinib can be administered with or without food (see section&nbsp;4.2).</p><p><strong>&nbsp;</strong></p><p><u>Distribution</u></p><p><u>&nbsp;</u></p><p>The geometric mean volume of distribution (V<sub>ss</sub>) of crizotinib was 1772&nbsp;L following intravenous administration of a 50&nbsp;mg dose, indicating extensive distribution into tissues from the plasma.</p><p>&nbsp;</p><p>Binding of crizotinib to human plasma proteins <em>in vitro </em>is 91% and is independent of medicinal product concentration. <em>In vitro</em> studies suggest that crizotinib is a substrate for P‑glycoprotein (P‑gp).</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p><u>&nbsp;</u></p><p><em>In vitro</em> studies demonstrated that CYP3A4/5 were the major enzymes involved in the metabolic clearance of crizotinib. The primary metabolic pathways in humans were oxidation of the piperidine ring to crizotinib lactam and <em>O</em>‑dealkylation, with subsequent Phase&nbsp;2 conjugation of <em>O</em>‑dealkylated metabolites.</p><p>&nbsp;</p><p><em>In vitro</em> studies in human liver microsomes demonstrated that crizotinib is a time‑dependent inhibitor of CYP2B6 and CYP3A (see section&nbsp;4.5). <em>In vitro</em> studies indicated that clinical drug‑drug interactions are unlikely to occur as a result of crizotinib‑mediated inhibition of the metabolism of medicinal products that are substrates for CYP1A2, CYP2C8, CYP2C9, CYP2C19 or CYP2D6.</p><p>&nbsp;</p><p><em>In vitro </em>studies showed that crizotinib is a weak inhibitor of UGT1A1 and UGT2B7 (see section&nbsp;4.5). However, <em>in vitro</em> studies indicated that clinical drug‑drug interactions are unlikely to occur as a result of crizotinib‑mediated inhibition of the metabolism of medicinal products that are substrates for UGT1A4, UGT1A6, or UGT1A9.</p><p>&nbsp;</p><p><em>In vitro</em> studies in human hepatocytes indicated that clinical drug‑drug interactions are unlikely to occur as a result of crizotinib‑mediated induction of the metabolism of medicinal products that are substrates for CYP1A2.</p><p><u>&nbsp;</u></p><p><u>Elimination</u></p><p><u>&nbsp;</u></p><p>Following single doses of crizotinib, the apparent plasma terminal half‑life of crizotinib was 42&nbsp;hours in patients.</p><p>&nbsp;</p><p>Following the administration of a single&nbsp;250&nbsp;mg radiolabelled crizotinib dose to healthy subjects, 63% and 22% of the administered dose was recovered in faeces and urine, respectively. Unchanged crizotinib represented approximately 53% and 2.3% of the administered dose in faeces and urine, respectively.</p><p>&nbsp;</p><p><u>Coadministration with medicinal products that are substrates of transporters</u></p><p><u>&nbsp;</u></p><p>Crizotinib is an inhibitor of P‑glycoprotein (P‑gp)<em> in vitro</em>. Therefore, crizotinib may have the potential to increase plasma concentrations of coadministered medicinal products that are substrates of P‑gp (see section&nbsp;4.5).</p><p>&nbsp;</p><p>Crizotinib is an inhibitor of OCT1 and OCT2 <em>in vitro</em>. Therefore, crizotinib may have the potential to increase plasma concentrations of coadministered medicinal products that are substrates of OCT1 or OCT2 (see section&nbsp;4.5).</p><p>&nbsp;</p><p><em>In vitro</em>, crizotinib did not inhibit the human hepatic uptake transport proteins organic anion transporting polypeptide (OATP)1B1 or OATP1B3 or the renal uptake transport proteins organic anion transporter (OAT)1 or OAT3 at clinically relevant concentrations. Therefore, clinical drug‑drug interactions are unlikely to occur as a result of crizotinib‑mediated inhibition of the hepatic or renal uptake of medicinal products that are substrates for these transporters.</p><p>&nbsp;</p><p><u>Effect on other transport proteins</u></p><p>&nbsp;</p><p><em>In vitro</em>, crizotinib is not an inhibitor of BSEP at clinically relevant concentrations.</p><p>&nbsp;</p><p><u>Pharmacokinetics in special patient groups</u></p><p><u>&nbsp;</u></p><p><em>Hepatic impairment</em></p><p>Crizotinib is extensively metabolised in the liver. Patients with mild (either AST&nbsp;&gt;&nbsp;ULN and total bilirubin&nbsp;&le;&nbsp;ULN or any AST and total bilirubin &gt;&nbsp;ULN but &pound;1.5&nbsp;&times;&nbsp;ULN), moderate (any AST and total bilirubin&nbsp;&gt;&nbsp;1.5&nbsp;&times;&nbsp;ULN and &le;&nbsp;3&nbsp;&times;&nbsp;ULN), or severe (any AST and total bilirubin&nbsp;&gt;&nbsp;3&nbsp;&times;&nbsp;ULN) hepatic impairment or normal (AST and total bilirubin&nbsp;&le;&nbsp;ULN) hepatic function, who were matched controls for mild or moderate hepatic impairment, were enrolled in an open‑label, non‑randomised clinical study (Study&nbsp;1012), based on NCI classification.</p><p>&nbsp;</p><p>Following crizotinib 250&nbsp;mg twice daily dosing, patients with mild hepatic impairment (N=10) showed similar systemic crizotinib exposure at steady state compared to patients with normal hepatic function (N=8), with geometric mean ratios for area under the plasma concentration‑time curve as daily exposure at steady state (AUC<sub>daily</sub>) and C<sub>max</sub> of 91.1% and 91.2%, respectively. No starting dose adjustment is recommended for patients with mild hepatic impairment.</p><p>&nbsp;</p><p>Following crizotinib 200&nbsp;mg twice daily dosing, patients with moderate hepatic impairment (N=8) showed higher systemic crizotinib exposure compared to patients with normal hepatic function (N=9) at the same dose level, with geometric mean ratios for AUC<sub>daily</sub> and C<sub>max</sub> of 150% and 144%, respectively. However, the systemic crizotinib exposure in patients with moderate hepatic impairment at the dose of 200&nbsp;mg twice daily was comparable to that observed from patients with normal hepatic function at a dose of 250&nbsp;mg twice daily, with geometric mean ratios for AUC<sub>daily</sub> and C<sub>max</sub> of 114% and 109%, respectively.</p><p>&nbsp;</p><p>The systemic crizotinib exposure parameters AUC<sub>daily</sub> and C<sub>max</sub> in patients with severe hepatic impairment (N=6) receiving a crizotinib dose of 250&nbsp;mg once daily were approximately 64.7% and 72.6%, respectively, of those from patients with normal hepatic function receiving a dose of 250&nbsp;mg twice daily.</p><p>&nbsp;</p><p>An adjustment of the dose of crizotinib is recommended when administering crizotinib to patients with moderate or severe hepatic impairment (see sections&nbsp;4.2 and 4.4).</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>Patients with mild (60&nbsp;&le;&nbsp;CL<sub>cr</sub>&nbsp;&lt;&nbsp;90 mL/min) and moderate (30&nbsp;&le;&nbsp;CL<sub>cr</sub>&nbsp;&lt;&nbsp;60&nbsp;mL/min) renal impairment were enrolled in single‑arm Studies&nbsp;1001 and 1005. The effect of renal function as measured by baseline CL<sub>cr</sub> on observed crizotinib steady-state trough concentrations (C<sub>trough, ss</sub>) was evaluated. In Study&nbsp;1001, the adjusted geometric mean of plasma C<sub>trough, ss</sub> in mild (N=35) and moderate (N=8) renal impairment patients were 5.1% and 11% higher, respectively, than those in patients with normal renal function. In Study&nbsp;1005, the adjusted geometric mean C<sub>trough, ss </sub>of crizotinib in mild (N=191) and moderate (N=65) renal impairment groups were 9.1% and 15% higher, respectively, than those in patients with normal renal function. In addition, the population pharmacokinetic analysis using data from Studies&nbsp;1001, 1005 and 1007 indicated CL<sub>cr</sub> did not have a clinically meaningful effect on the pharmacokinetics of crizotinib. Due to the small size of the increases in crizotinib exposure (5%‑15%), no starting dose adjustment is recommended for patients with mild or moderate renal impairment.</p><p>&nbsp;</p><p>After a single&nbsp;250&nbsp;mg dose in subjects with severe renal impairment (CL<sub>cr</sub>&nbsp;&lt;&nbsp;30&nbsp;mL/min) not requiring peritoneal dialysis or haemodialysis, crizotinib AUC<sub>inf</sub> and C<sub>max</sub> increased by 79% and 34%, respectively, compared to those with normal renal function. An adjustment of the dose of crizotinib is recommended when administering crizotinib to patients with severe renal impairment not requiring peritoneal dialysis or haemodialysis (see sections&nbsp;4.2 and 4.4).</p><p>&nbsp;</p><p><em>Age</em></p><p>Based on the population pharmacokinetic analysis of data from Studies&nbsp;1001, 1005, and 1007, age has no effect on crizotinib pharmacokinetics (see sections&nbsp;4.2 and 5.1).</p><p>&nbsp;</p><p><em>Body weight and gender</em></p><p>Based on the population pharmacokinetic analysis of data from Studies&nbsp;1001, 1005 and 1007, there was no clinically meaningful effect of body weight or gender on crizotinib pharmacokinetics.</p><p>&nbsp;</p><p><em>Ethnicity</em></p><p>Based on the population pharmacokinetic analysis of data from Studies&nbsp;1001, 1005 and 1007, the predicted area under the plasma concentration‑time curve at steady‑state (AUC<sub>ss</sub>) (95%&nbsp;CI) was 23%‑37% higher in Asian patients (N=523) than in non‑Asian patients (N=691).</p><p>&nbsp;</p><p>In studies in patients with ALK‑positive advanced NSCLC (N=1669), the following adverse reactions were reported with an absolute difference of &ge;&nbsp;10% in Asian patients (N=753) than in non‑Asian patients (N=916): elevated transaminases, decreased appetite, neutropenia, and leukopenia. No adverse drug reactions were reported with an absolute difference of &ge;&nbsp;15%.</p><p>&nbsp;</p><p><em>Geriatric</em></p><p>Limited data are available in this subgroup of patients (see sections&nbsp;4.2 and 5.1). Based on the population pharmacokinetic analysis of data in Studies&nbsp;1001, 1005 and 1007, age has no effect on crizotinib pharmacokinetics.</p><p>&nbsp;</p><p><u>Cardiac electrophysiology</u></p><p><u>&nbsp;</u></p><p>The QT&nbsp;interval prolongation potential of crizotinib was assessed in patients with either ALK‑positive or ROS1‑positive NSCLC who received crizotinib 250&nbsp;mg twice daily. Serial ECGs in triplicate were collected following a single dose and at steady state to evaluate the effect of crizotinib on QT&nbsp;intervals. Thirty‑four of 1619&nbsp;patients (2.1%) with at least 1&nbsp;postbaseline ECG assessment were found to have QTcF&nbsp;&ge;&nbsp;500&nbsp;msec, and 79 of 1585&nbsp;patients (5.0%) with a baseline and at least 1&nbsp;postbaseline ECG assessment had an increase from baseline QTcF&nbsp;&ge;&nbsp;60&nbsp;msec by automated machine-read evaluation of ECG (see section&nbsp;4.4).</p><p>&nbsp;</p><p>An ECG substudy using blinded manual ECG measurements was conducted in 52&nbsp;ALK‑positive NSCLC patients who received crizotinib 250&nbsp;mg twice daily. Eleven&nbsp;(21%)&nbsp;patients had an increase from Baseline in QTcF&nbsp;value&nbsp;&ge;&nbsp;30 to &lt;&nbsp;60&nbsp;msec and 1&nbsp;(2%)&nbsp;patient had an increase from Baseline in QTcF&nbsp;value of &ge;&nbsp;60&nbsp;msec. No patients had a maximum QTcF&nbsp;&ge;&nbsp;480&nbsp;msec. The central tendency analysis indicated that all upper limits of the 90%&nbsp;CI for the LS mean change from Baseline in QTcF at all Cycle&nbsp;2 Day&nbsp;1 time points were &lt;&nbsp;20&nbsp;msec. A pharmacokinetic/pharmacodynamic analysis suggested a relationship between crizotinib plasma concentration and QTc. In addition, a decrease in heart rate was found to be associated with increasing crizotinib plasma concentration (see section&nbsp;4.4), with a maximum mean reduction of 17.8&nbsp;beats&nbsp;per&nbsp;minute (bpm) after 8&nbsp;hours on Cycle&nbsp;2 Day&nbsp;1.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In rat and dog repeat-dose toxicity studies up to 3-month duration, the primary target organ effects were related to the gastrointestinal (emesis, faecal changes, congestion), haematopoietic (bone marrow hypocellularity), cardiovascular (mixed ion channel blocker, decreased heart rate and blood pressure, increased LVEDP, QRS and PR intervals, and decreased myocardial contractility), or reproductive (testicular pachytene spermatocyte degeneration, single-cell necrosis of ovarian follicles) systems. The No Observed Adverse Effect Levels (NOAEL) for these findings were either subtherapeutic or up to 2.6-fold human clinical exposure based on AUC. Other findings included an effect on the liver (elevation of liver transaminases) and retinal function, and potential for phospholipidosis in multiple organs without correlative toxicities.</p><p>&nbsp;</p><p>Crizotinib was not mutagenic <em>in vitro</em> in the bacterial reverse mutation (Ames) assay. Crizotinib was aneugenic in an <em>in vitro</em> micronucleus assay in Chinese Hamster Ovary cells and in an <em>in vitro</em> human lymphocyte chromosome aberration assay. Small increases of structural chromosomal aberrations at cytotoxic concentrations were seen in human lymphocytes. The NOAEL for aneugenicity was approximately 1.8-fold human clinical exposure based on AUC.</p><p>&nbsp;</p><p>Carcinogenicity studies with crizotinib have not been performed.</p><p>&nbsp;</p><p>No specific studies with crizotinib have been conducted in animals to evaluate the effect on fertility; however, crizotinib is considered to have the potential to impair reproductive function and fertility in humans based on findings in repeat-dose toxicity studies in the rat. Findings observed in the male reproductive tract included testicular pachytene spermatocyte degeneration in rats given &ge;50&nbsp;mg/kg/day for 28&nbsp;days (approximately 1.1-fold human clinical exposure based on AUC). Findings observed in the female reproductive tract included single-cell necrosis of ovarian follicles of a rat given 500&nbsp;mg/kg/day for 3&nbsp;days.</p><p>&nbsp;</p><p>Crizotinib was not shown to be teratogenic in pregnant rats or rabbits. Post-implantation loss was increased at doses &ge;50&nbsp;mg/kg/day (approximately 0.4 times the AUC at the recommended human dose) in rats, and reduced fetal body weights were considered adverse effects in the rat and rabbit at 200 and 60&nbsp;mg/kg/day, respectively (approximately 1.2-fold human clinical exposure based on AUC).</p><p><strong>&nbsp;</strong></p><p>Decreased bone formation in growing long bones was observed in immature rats at 150&nbsp;mg/kg/day following once daily dosing for 28&nbsp;days (approximately 3.3 times human clinical exposure based on AUC). Other toxicities of potential concern to paediatric patients have not been evaluated in juvenile animals.</p><p>&nbsp;</p><p>The results of an <em>in vitro</em> phototoxicity study demonstrated that crizotinib may have phototoxic potential.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Capsule content</u></p><p>Colloidal anhydrous silica</p><p>Microcrystalline cellulose</p><p>Anhydrous calcium hydrogen phosphate</p><p>Sodium starch glycolate (Type A)</p><p>Magnesium stearate</p><p>&nbsp;</p><p><u>Capsule shell</u></p><p>Gelatin</p><p>Titanium dioxide (E171)</p><p>Red iron oxide (E172)</p><p>&nbsp;</p><p><u>Printing ink</u></p><p>Shellac</p><p>Propylene glycol</p><p>Potassium hydroxide</p><p>Black iron oxide (E172)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Keep out of the sight and reach of children.</p><p>&nbsp;</p><p>Store below 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>XALKORI</u><u> 200&nbsp;mg hard capsules</u></p><p>HDPE bottles with a polypropylene closure containing 60 hard capsules.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>XALKORI 250&nbsp;mg hard capsules</u></p><p>HDPE bottles with a polypropylene closure containing 60 hard capsules.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                	Pfizer Limited
Ramsgate Road, Kent CT13 9NJ, Sandwich, United Kingdom

	Manufactured by:

Pfizer Manufacturing Deutschland GmbH 
(Betriebsstätte Freiburg)
Freiburg, Germany.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                June 2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>